AU2014221245A1 - Cationic transition metal catalysts - Google Patents

Abstract

H.\ur,1em'oven\RPorthDCC\AAR\6708223 .DOC-4k9/2014 - 83 The present disclosure includes catiome complexes of iron, ruthenium and osmium, and their use as catalysts in organic synthesis transformations including the hydrogenation of unsaturated compounds. The complexes are represented by the following formulae I, II, III, IV and V, wherein M is Fe, Ru or Os, P is a monodentate ligand with a phosphorus donor atom, P2 is a bidentate neutral ligand with two phosphorus donor atoms, N2 is a bidentate neutral ligand with two nitrogen donor atoms, PN is a bidentate neutral ligand with phosphorus and nitrogen donor atoms, PNNP is a tetradentate neutral ligand bonded to M via two phosphorus and two nitrogen atoms, X is any anionic ligand, LB is any neutral Lewis base, Y is any non-coordmatmg anion, n is 0, 1 or 2, m is 1 or 2, q is 0 or 1, r is I or 2 and q + r = 2.

Description

CATIONIC TRANSITION METAL CATALYSTS This application is a divisional of Australian Application No. 2008318239, the entire contents of which are incorporated herein by reference. FIELD OF THE DISCLOSURE The present disclosure relates to the field of catalytic reactions, in 5 which a catalytic system comprising a cationic metal complex is used for organic chemical synthesis, for example, but not limited to the hydrogenation or reduction of compounds containing a carbon-carbon (C=C) or a carbon-heteroatom (C=0, C=N) double bond. BACKGROUND OF THE DISCLOSURE 10 The catalysis approach towards synthesis offers several distinct advantages (e.g. cost savings, less waste generation) over more traditional protocols using stoichiometric reagents. In particular, transition metal (TM) catalysis has revolutionized organic synthesis (Tsuji, J. Transition Metal Reagens and Catalysts; Wiley: West Sussex, England, 2002). The near constant 15 improvement in the field of TM catalysis is undoubtedly due in large part to the introduction of new and improved ligands, which allows for desired transformations to be carried out in a more efficient manner (i.e. milder conditions, lower catalyst loadings, higher yields and higher enantioselectivities when applicable). 20 Catalytic hydrogenation is one of the fundamental reactions in chemistry, and is used in a large number of chemical processes. It is now recognized that catalytic hydrogenations of carbon-carbon double bonds of alkenes, and carbon heteroatom double bonds of ketones, aldehydes and imines are indispensable processes for the production of the wide range of alkanes, alcohols and amines, 25 including chiral compounds, which are useful as valuable end products and precursors for the pharmaceutical, agrochemical, flavor, fragrance, material and fine chemical industries. Amongst the several different kinds of processes known to achieve such transformation, two important types are: (a) transfer hydrogenation processes, in 30 which hydrogen-donors such as secondary alcohols, and in particular isopropanol ('PrOH), and triethlammonium formate (HCOOH/NEt 3 ) are used, (b) hydrogenation processes, in which molecular hydrogen is used. Both hydrogen transfer and WO 2009/055912 PCT/CA2008/001905 2 hydrogenation processes need a catalyst or catalytic system to activate the reducing agent, such as an alcohol, HCOOH/NEt 3 or molecular hydrogen. The catalytic hydrogenation processes developed by Noyori and coworkers (Ohkuma et al., J. Am. Chem. Soc., 1995, 107, 2675 and 10417) are very 5 attractive, since the catalysts consist of air-stable ruthenium complexes of the type RuCI 2

(PR

3 )2(diamine) and RuCI 2 (diphosphine)(diamine) which are precursors for the generation of what appears to be some of the most active catalysts for the homogeneous and asymmetric hydrogenation of ketones and imines in the presence of a base and hydrogen gas. It has been proposed and subsequently mechanistically 10 elucidated that the key molecular recognition feature of these catalysts is the presence of mutually cis N-H and Ru-H moieties of the catalytic dihydride species (RuH 2

(PR

3

)

2 (diamine) and RuH2(diphosphine)(diamine)) that electronically bind and activate the substrate and facilitate reduction. Other reactions for which transition metal catalysts have found 15 significant applications include hydroformylations, hydrosilylations, hydroborations, hydroaninations, hydrovinylations, hydroarylations, hydrations, oxidations, epoxidations, reductions, C-C and C-X bond formations (includes reactions such as Heck, Suzuki-Miyaura, Negishi, Buchwald--Hartwig Amination, a-Ketone Arylation, N-Aryl Amination, Murahashi, Kumada, Negishi and Stille reactions etc.), functional 20 group interconversions, kinetic resolutions, dynamic kinetic resolutions, cycloadditions, Diels-Alder reactions, retro-Diels-Alder reactions, sigmatropic rearrangements, electrocyclic reactions, ring-opening and/or ring-closing olefin metatheses, carbonylations, and aziridinations. SUMMARY OF THE DISCLOSURE 25 The hydrogenation of ketones has been successfully and advantageously performed using cationic salts of certain neutral Fe(II), Ru(II) and Os(II) complexes. The cationic complexes were prepared by treatment of the neutral precursors with anion abstracting agents. The resulting complexes are air and moisture stable. Solutions can be prepared and handled in air with no obvious signs of 30 decay. The activity of the cationic complexes matches that of the neutral precursors. In several cases, the cationic derivatives give products with improved enantiomeric excess relative to the neutral congener.

WO 2009/055912 PCT/CA2008/001905 3 Accordingly, the present disclosure provides a compound selected from a compound of Formula I, II, III, IV and V: [M(P2)(PN)Xq(LB)j"'[Y], (I) 5 [M(PN) 2 Xq(LB).]"[TJ, (II) [M(P)m(N 2 )X(LB)n]"[Y]r (III) [M(PNNP)X(LB)]+[Y], (IV) and

[M(P

2

)(N

2 )X(LB)n]j[Y-j (V) 10 wherein M is Fe, Ru or Os; P is a monodentate ligand bonded to M via a phosphorus atom;

P

2 is a bidentate neutral ligand bonded to M via two phosphorus atoms;

N

2 is a bidentate neutral ligand bonded to M via two nitrogen atoms; 15 PN is a bidentate neutral ligand bonded to M via a phosphorus atom and a nitrogen atom; PNNP is a tetradentate neutral ligand bonded to M via two phosphorus and two nitrogen atoms; X is any anionic ligand; 20 LB is any neutral Lewis base; Y is any non-coordinating anion; n is 0, 1 or 2; m is 1 or 2; and q is 0 or 1; 25 r is 1 or 2; and q +r=2. Also included in the present disclosure is a process for preparing a compound of the disclosure comprising combining a precursor metal compound, an anion abstracting agent, and one or more P, P 2 , N 2 , PN or PNNP ligands, and 30 optionally a base and reacting under conditions to form the compound of the disclosure and optionally isolating the compound of the disclosure.

WO 2009/055912 PCT/CA2008/001905 4 The present disclosure also includes a method for catalyzing a synthetic organic reaction comprising combining starting materials for the reaction with a compound according to the disclosure under conditions for performing the reaction. 5 The present disclosure also includes the use of a compound of the disclosure for catalyzing a synthetic organic reaction. The synthetic organic transformations to which the compounds of the disclosure can be applied include but are not limited to: hydrogenations, transfer hydrogenations, hydroformylations, hydrosilylations, hydroborations, 10 hydroaminations, hydrovinylations, hydroarylations, hydrations, oxidations, epoxidations, reductions, C-C and C-X bond formations (including, for example, Heck, Suzuki-Miyaura, Negishi, Buchwald-Hartwig Amination, a-Ketone Arylation, N-Aryl Amination, Murahashi, Kumada, Negishi and Stille reactions etc.), functional group interconversions, kinetic resolutions, dynamic kinetic resolutions, 15 cycloadditions, Diels-Alder reactions, retro-Diels-Alder reactions, sigmatropic rearrangements, electrocyclic reactions, ring-openings, ring-closings, olefin metatheses, carbonylations, and aziridinations. In all transformations listed above the reactions may or may not be regioselective, chemoselective, stereoselective or diastereoselective. 20 In an embodiment, the present disclosure relates to a process for the reduction of compounds comprising a carbon-carbon (C=C), carbon-oxygen (C=0) or carbon-nitrogen (C=N) double bond, to the corresponding hydrogenated alkane, alcohol or amine, comprising contacting a compound comprising the C=C, C=Q or C=N double bond with a catalyst of the Formula (I), (II), (III), (IV) or (V) under 25 hydrogenation conditions. Other features and advantages of the present disclosure will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the disclosure are given by way of illustration only, since various 30 changes and modifications within the spirit and scope of the disclosure will become apparent to those skilled in the art from this detailed description. BRIEF DESCRIPTION OF THE DRAWINGS WO 2009/055912 PCT/CA2008/00190 5 5 The present disclosure will now be described in greater detail with reference to the attached drawings in which: Figure I is an X-ray crystal structure of [RuCI(pyridine)(R-binap)(RR-cydn)]BF4. Hydrogen atoms, BF 4 anion and two CHC1 3 molecules omitted for clarity. 5 DETAILED DESCRIPTION OF THE DISCLOSURE (I) DEFINTIONS The term "C.,nalkyl" as used herein means straight and/or branched chain, saturated alkyl radicals containing from one to "n" carbon atoms and includes (depending on the identity of n) methyl, ethyl, propyl, isopropyl, n-butyl, s-butyl, 10 isobutyl, t-butyl, 2,2-dimethylbutyl, n-pentyl, 2-methylpentyl, 3-methylpentyl, 4 methylpentyl, n-hexyl and the like, where the variable n is an integer representing the largest number of carbon atoms in the alkyl radical. The term "C.

1 alkenyl" as used herein means straight and/or branched chain, unsaturated alkyl radicals containing from one to n carbon atoms and one to 15 three double bonds, and includes (depending on the identity of n) vinyl, allyl, 2 methylprop-1-enyt, but-1-enyl, but-2-enyl, but-3-enyl, 2-methylbut-1-enyt, 2 methylpent-l-enyl, 4-methylpent-l-enyl, 4-methylpent-2-enyl, 2-methylpent-2-enyl, 4-methylpenta-1,3-dienyl, hexen-1-yl and the like, where the variable n is an integer representing the largest number of carbon atoms in the alkenyl radical. 20 The term "C3.,cycloalkyl" as used herein means a monocyclic or polycyclic saturated carbocylic group containing from three to n carbon atoms and includes (depending on the identity of n), cyclopropyl, cyclobutyl, cyclopentyl, cyclodecyl, bicyclo[2.2.2]octane, bicyclo[3.1.1]heptane and the like, where the variable n is an integer representing the largest number of carbon atoms in the 25 cycloalkyl group. The term "aryl" as used herein means a monocyclic, bicyclic or tricyclic aromatic ring system containing at least one aromatic ring and from 6 to 14 carbon atoms and includes phenyl, naphthyl, anthracenyl, 1,2-dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, fluorenyl, indanyl, indenyl and the like, 30 The term "heterocyclic" as used herein means a monocyclic, bicyclic or tricyclic ring system containing from 5 to 14 atoms of which, unless otherwise specified, one, two, three, four or five are heterornoieties independently selected from WO 2009/055912 PCT/CA2008/001905 6 N, NR, NRbRC, 0, S, SIR 8 and SiRbR*, wherein R is selected from H, C 1 .6alkyl, =0 and OH and Rb and R* are independently selected from H and Cifalkyl. When the ring system includes at least one aromatic ring it is referred to as "heteroaryl". Heterocylic groups include, for example, thienyl, furyl, pyrrolyl, pyrididyl, indolyl, 5 quinolyl, isoquinolyl, tetrahydroquinolyl, benzofuryl, benzothienyl and the like. The term "halo" as used herein means halogen and includes chloro, fluoro, bromo, iodo and the like. The term "fluoro-substituted" as used herein means that one or all of the hydrogens on the referenced group is replaced with fluorine. 10 The suffix "ene" added on to any of the above groups means that the group is divalent, i.e. inserted between two other groups. The term "ring system" as used herein refers to a carbon-containing ring system, that includes monocycles, fused bicyclic and polycyclic rings, bridged rings and metalocenes, Where specified, the carbons in the rings may be substituted 15 or replaced with heteroatoms. The term "polycyclic" as used herein means groups that contain more than one ring linked together and includes, for example, groups that contain two (bicyclic), three (tricyclic) or four (quadracyclic) rings. The rings may be linked through a single bond, a single atom (spirocyclic) or through two atoms (fused and 20 bridged). The term "non-coordinating anion" as used herein refers to an anion which does not formally bond to or share electrons with the metal center in a covalent bond. The term "joined together" as used herein means that two substituents 25 are linked together via a linker grouping to form a ring system. The linker grouping comprises at least one atom but may also comprise several atoms, for example up to 20 atoms, resulting in the formation of monocyclic and polycyclic ring systems. The term "compound(s) of the disclosure" means a compound of the Formula (I), (II), (III), (IV) or (V), or mixtures thereof 30 In understanding the scope of the present disclosure, the term "comprising" and its derivatives, as used herein, are intended to be open ended terms that specify the presence of the stated features, elements, components, groups, WO 2009/055912 PCT/CA2008/001905 7 integers, and/or steps, but do not exclude the presence of other unstated features, elements, components, groups, integers and/or steps. The foregoing also applies to words having similar meanings such as the terms, "including", "having" and their derivatives. Finally, terms of degree such as "substantially", "about" and 5 "approximately" as used herein mean a reasonable amount of deviation of the modified term such that the end result is not significantly changed. These terms of degree should be construed as including a deviation of at least ±5% of the modified term if this deviation would not negate the meaning of the word it modifies. (II) COMPOUNDS OF THE DISCLOSURE 10 Rendering the neutral metal complexes of the present disclosure into an ionic pair dramatically altered the behaviour and properties of the original metal complex. These changes may be borne out of changes in structure of the resulting complex, the charged nature of the newly formed ionic complex or they may be a result of qualities imparted by the new counter ion. Regardless of the origin of effect, 15 there were great advantages gained from this approach in the present disclosure. Removal of any coordinating ligand from the metal complexes of the present disclosure had the effect of introducing a vacant coordination site. In transition-metal catalysis this is often imperative for substrate binding and may indeed be rate limiting with respect to the catalytic cycle. Abstraction of one or two anionic 20 ligands and substituting them with non- or weakly coordinating anions represents one such method for installing a vacant coordination site. In this manner, generating cationic complexes by abstraction of coordinating anionic ligands and substitution with non-coordinating anionic ligands lead to more active catalysts. The exchange of one or two coordinating anionic ligands with non 25 coordinating or weakly coordinating ligands resulted in a more electrophilic, cationic metal centre. This increased electrophilicity lead to stronger binding between the metal and nucleophilic substrates. With respect to catalytic processes involving metal substrate interactions, this has the obvious consequences and is especially beneficial in the case of weaker nucleophiles such as those with electron-withdrawing groups. 30 Transforming the covalent metal complexes of the present disclosure into ionic salts lead to derivatives which were more stable than their parents. Without wishing to be limited by theory, increased stability is the result of the removal of WO 2009/055912 PCT/CA2008/001905 8 electron density from the metal leading to a metal centre which is less readily oxidized, Thus, the ionic salts prepared from neutral precursors were generally more stable to oxidation under atmospheric conditions displaying greater tolerance toward oxygen and moisture and greater storage stability (i.e. shelf-life). 5 The solubility properties of ionic complexes were also different from their neutral precursors, Generally, ionic complexes tended to be more soluble in polar solvents and less soluble in apolar solvents. Some ionic complexes were also more soluble in aqueous solutions. That being said, the solubility of the ionic complex can be further tuned with the selection of the anion. For instance, highly fluorinated 10 anions tended to impart a high degree of solubility in a broad range of solvents. In fact, many ionic complexes incorporating highly fluorinated anions were more soluble in nonpolar solvents than the corresponding neutral precursor while their solubility in polar solvents remained high owing to the ionic nature of the complex. The ability to tailor solubility also afforded the ability to control the 15 solid properties of the ionic complex. That is, polar salts could be readily precipitated with nonpolar solvents leading to higher isolated yields and more regular and controllable particle sizes. A corollary to this property is that these ionic catalysts also hold the promise of more facile removal from product mixtures. An obvious benefit when one considers the use of ionic catalysts in applications where low residual 20 metals are imperative. While rendering a neutral catalyst cationic holds the promise of many critical advantages, the utility of this approach is limited by competence in catalysis of the resulting ionic complex. If the derived ionic catalyst is no longer active in catalysis then the advantages described above are obviously moot. In the present 25 disclosure, the cationic ruthenium catalysts were shown to be excellent hydrogenation catalysts. The activity of the cationic complexes matched that of the neutral precursors and, in several cases, the cationic derivatives gave products with improved enantiomeric excess relative to the neutral congener. While not wishing to be limited by theory, this is likely due to the fact that the cationic complexes disclosed herein are 30 more reliably and reproducibly activated prior to entering the catalytic cycle. That is to say that while all of the complexes are subject to activation, the cationic complexes fare better in this process than the neutral analogues. The activation process, which is WO 2009/055912 PCT/CA2008/001905 9 carried out in alcohol solvents and is often irreproducible and unpredictable, is better suited to the cationic complexes since they are soluble in the solvent system while the neutral complexes are either insoluble or moderately soluble. The poor solubility of the neutral compounds means that the activation is often incomplete and can lead to 5 side reactions giving catalytically inactive species or active species which do not retain the desired stereoselectivity. Accordingly, the present disclosure provides a compound selected from a compound of Formula I, II, III, IV and V: 10 [M(P2)(PN)X(LB)]r'[Y]r (I) [M(PN)2X(LB)n][Y]r (II) [M(P)m(N2)Xq(LB)nl" t [Y]r (111) [M(PNNP)X(LB)n]l[Yir (IV) and [M(P2)(N 2 )X(LB).]n[lYr (V) 15 wherein M is Fe, Ru or Os; P is a monodentate ligand bonded to M via a phosphorus atom;

P

2 is a bidentate neutral ligand bonded to M via two phosphorus atoms; 20 N 2 is a bidentate neutral ligand bonded to M via two nitrogen atoms; PN is a bidentate neutral ligand bonded to M via a phosphorus atom and a nitrogen atom; PNNP is a tetradentate neutral ligand bonded to M via two phosphorus and two nitrogen atoms; 25 X is any anionic ligand; LB is any neutral Lewis base; Y is any non-coordinating anion; n is 0, 1 or 2; m is I or 2; 30 q is 0 or 1; r is 1 or 2; and q + r=2.

WO 2009/055912 PCT/CA2008/001905 10 In an embodiment of the disclosure, P is a monodentate phosphine ligand of the Formula (VI):

PRR

2

R

3 (VI) 5 wherein R 1 , R2 and R 3 are independently selected from C6-isaryl, C 1 2 oalkyl and C 3 . 20Cycloalkyl, each being optionally substituted with one to five substituents independently selected from C 1 6 alkyl, fluoro-substituted Ci 6 alkyl, halo, CI.6alkoxy, fluoro-substituted Ci 6 alkoxy and C6-I4aryl. In further embodiments of the disclosure, 10 R', R 2 and R are independently selected from phenyl, C 16 alkyl and C 310 cycloalkyl, each being optionally substituted vith one to three substituents independently selected from C 14 alkyl, fluoro-substituted C 1 4 alkyl, halo, C 1 4 alkoxy and fluoro-substituted

C

16 alkoxy. In further embodiments of the disclosure, R1, R2 and R3 are all cyclohexyl, phenyl, xylyl or tolyl. 15 In another embodiment of the disclosure, P 2 is a bidentate bisphosphino ligand of the Formula (VII):

R

4

R'P-Q'-PR

6 R' (VII) 20 wherein R4, R5, R6 and R 7 are, independently, as defined for R 1 , R2 and R , and Q is selected from unsubstituted or substituted Ci-Cioalkylene and unsubstituted or substituted C-Csalkenylene where the substituents on Q1 are independently selected from one or more of Ci 6 alkyl, fluoro-substituted Ci 6 alkyl, halo, Cl6alkoxy, fluoro substituted C 16 alkoxy and unsubstituted or substituted C6.1 4 ary and/or two 25 substituents on Q1 are joined together to form, including the carbon atoms to which they are attached, one or more unsubstituted or substituted 5-20-membered monocyclic, polycyclic, heterocyclic, carbocyclic, saturated, unsaturated or metallocenyl ring systems, and Q 1 is chiral or achiral. In further embodiments of the disclosure, R4, R5, R6 and R 7 are independently selected from phenyl, C1.aalkyl and 30 C3rocycloalkyl, each being optionally substituted with one to three substituents independently selected from C1 4 alkyl, fluoro-substituted C 14 alkyl, halo, CI4alkoxy and fluoro-substituted C 1 4 alkoxy and Q' is selected from unsubstituted or substituted WO 2009/055912 PCT/CA2008/001905 11 CI-Csalkylene where the substituents on Q' are independently selected from one to four C.

4 alkyl, fluoro-substituted Ci 4 alkyl halo, Ci 4 alkoxy, fluoro-substituted C1 4alkoxy, unsubstituted and substituted phenyl and substituted and unsubstituted naphthyl, or two substituents are joined together to form, including the carbon atoms 5 to which they are attached, one or more unsubstituted or substituted phenylene, cyclohexylene, naphthylene, pyridylene or ferrocenylene groups, and Q1 is chiral or achiral. In further embodiments of the disclosure, R 4 , R, R 0 and R are all cyclohexyl, phenyl, xylyl or tolyl. Unless otherwise specified, the term substituted means that one or more, including all, but suitably one to five, of the available 10 hydrogen atoms on a group are replaced with C 1

.

6 alkyl, fluoro-substituted C 16 alkyl, Cg- 6 alkoxy, fluoro-substituted C 1 4alkyl, halo or C 6 j4aryl. Representative examples of the preparation of bis(phosphino) ligands are found in Gupta, M. et al. Chem. Commun. 1996, 2083-2084; Moulton, C.J. J. Chem. Soc. Dalton, 1976, 1020-1024). Other bis(phosphino) ligands are selected from: 15 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl (BINAP); 2,2'-bis(diphenylphosphino)-5,5',6,6',7,7',8,8'-octabydro-l,1'-binaphthyl (H 8 BINAP); 2,2'-bis-(diphenylphosphino)-6,6'-dimethyl- ,1'-binaphthyl (6MeBINAP); 2,2'-bis-(di-p-tolylphosphino)-1-,I'-binaphthyl (Tol-BINAP); 2,2'-bis[bis(3-methylphenyl)phosphino]-1,1'-binaphthyl; 20 2,2'-bis[bis(3,5-di-tert-butylphenyl)phosphino]-1,1-binaphthyl; 2,2'-bis[bis(4-tert-butylphenyl)phosphino]-1, '-binaphthyl; 2,2'-bis[bis(3,5-dimethylphenyl)phosphino]-1,1'-binaphthyl (Xyl-BINAP); 2,2'-bis[bis(3,5-dimethyl-4-methoxyphenyl)phosphino]- 1,1 '-binaphthyl (Dmanyl BINAP); 25 2,2'-bis[bis-(3,5-dimethylphenyl)phosphino] -6,6'-dimethyl- 1, 1-binaphthyl (Xyl 6MeBINAP); 3,3'-bis-(diphenylphosphanyl)- 13,13'-dimethyl 12,13,14,15,16,17,12',13',14',15',16',17'-dodecahydro-l l H,1I'H [4,4']bi[cyclopenta[a]phenanthrenyl]; 30 WO 2009/055912 PCT/CA2008/001905 12 PCy 2 PCy 2 wherein Cy is C 5 -gcycloalkyl; ocH3 N

H

3 CO PAr 2

H

3 CO PAr 2 NJ 5

OCH

3 where Ar is phenyl (PPhos), xylyl (XylPPhos) or tolyl (TolPPhos); PAr 2 PAr 2 10 where Ar is phenyl (PhanePhos), xylyl (XylPhanePhos) or tolyl (TolPhanePhos); and optical isomers thereof and mixtures of optical isomers in any ratio. In another embodiment of the disclosure, PN is a ligand of the Formula (VIII): 15 R 8

R

9

P-Q

2 -- NR"'R" (VIII) wherein R8 and R9 are, independently as defined for R 1 -R3; Q2 is as defined for Q'; and R1 0 and R" are independently selected from H, C 6 -isaryl, C 1 2 oalkyl and C 3 20 iocycloalkyl, each being optionally substituted with one to five substituents independently selected from CIsalkyl, fluoro-substituted C 1

.

6 alkyl halo, C 1

.

6 alkoxy, fluoro-substituted C 16 alkoxy and C.l4aryl, or WO 2009/055912 PCT/CA2008/001905 13 R10 and R" are joined to form, together with the nitrogen atom to which they are attached, a saturated, unsaturated or aromatic, monocyclic or polycyclic, substituted or unsubstituted ring system containing from 3 to 14 atoms, or one of R' 0 or R" are joined with a substituent on Q2 to form, together with the 5 nitrogen atom to which R' 0 and R" is attached, a 4- to 10-membered saturated, unsaturated or aromatic, monocyclic or bicyclic ring system, where if the nitrogen atom is part of aromatic ring or is bonded to an adjacent atom via a double bond, the other of R' 0 and R" is non-existent. In embodiments of the disclosure, R 8 and R 9 are independently selected from phenyl, Cs.

6 alkyI and fluoro-substituted C 1 6 alkyl, with 10 the phenyl being optionally substituted with one to five substituents independently selected from C 1 4 alkyl, fluoro-substituted C 14 alkyl halo, C1 4 alkoxy and fluoro substituted CI- 4 alkoxy and Q 2 is selected from unsubstituted or substituted C Csalkenylene where the substituents on Q2 are independently selected from one to four of Ci 6 alkyl, fluoro-substituted Cisalkyl, halo, Cl6alkoxy, fluoro-substituted C 1 . 15 6 alkoxy and unsubstituted or substituted phenyl and/or two substituents on Q2 are joined together to form, including the carbon atoms to which they are attached, one or more unsubstituted or substituted phenylene, naphthylene or ferrocenylene ring systems, and Q 2 is chiral or achiral. In further embodiments of the disclosure, R 8 and Rare all phenyl, tolyl or xylyl. In further embodiments, R' and R" and both H. In a 20 further embodiment, one of R' 0 or R" is joined with a substituent on Q2 to form, together with the nitrogen atom to which R' 0 and R" is attached, a substituted or unsubstituted pyridine ring and the other of one of R' 0 or R" is not present. Unless otherwise specified, the term substituted means that one or more, including all, but suitably one to five, of the available hydrogen atoms on a group are replaced with C I 25 6 alkyl, fluoro-substituted Ci- 6 alkyl, Ci 6 alkoxy, fluoro-substituted C1.

6 alkoxy, halo or

C

6 .1 4 aryl. Examples of PN ligands, include, for example, Ph 2

PCH

2

CH

2 NH2 (abbreviated as PGly), and: PAr 2 c NH 2 Ph Ph Ph H CH3 Fe \ H or Ar 2 P NH 2 Ar 2 P NH 2 PCT/CA2008/001905 26 June 2009 26-06-2009 14 AMENDED PCT ART 34 wherein Ar is selected from Ph, tolyl and xylyl, and optical isomers thereof and mixtures of optical isomers, In a further embodiment of the disclosure, PNNP is a tetradentate 5 diaminodiphosphine of the formula (IXa) or a diiminodiphosphine ligand of the Formula (IXb): R1R P-Q'-NRM-Q4-NR Q PR'R" (IXa)

R'

2

R'

3

P-Q

3 =N-Q4-N=Q-PR 16

R

7 (IXb) 10 wherein R", R", R 16 and R' 7 are independently as defined for R'-R, R" and R" are independently as defined for R'" and R" and Q 3 , Q 4 and Q 5 are independently as defined for Q1. In further embodiments of the disclosure, R' 2 , R5, R1 6 and R 7 are independently selected from phenyl, C.6alkyl and C 3 .1 0 cycloalkyl, each being 15 optionally substituted with one to five substituents independently selected from C, 4alkyi, fluoro-substituted C 1 4 alkyl, halo, C4alkoxy and fluoro-substituted C 1 ,alkoxy and Q 3 , Q 4 and Q 5 are independently selected from unsubstituted or substituted C, Csalkylene and from unsubstituted or substituted Cl-Cgalkenylene, where the substituents on Q 3 , Q4 and Q 5 are independently selected from one to four C4alkyl, 20 fluoro-substituted Cj4alkyl, halo, C 1 .alkoxy, fluoro-substituted C 1

.

6 alkoxy, unsubstituted and substituted phenyl and substituted and unsubstituted naphthyl or two substituents are joined together to form, including the carbon atoms to which they are attached, one or more unsubstituted or substituted phenyl, cyclohexyl, naphithyl or ferrocenyl groups, and Q 3 , Q 4 and Q 5 are chiral or achiral. In further embodiments of 25 the disclosure, R 2 , R' 3 , R" and R are all phenyl, tolyl or xylyl. Unless otherwise specified, the term substituted means that one or more, including all, but suitably one to five, of the available hydrogen atoms on a group are replaced with C 1 .alkyl, fluoro-substituted CI6alkyl, Cl6alkoxy, fluoro-substituted Ci6alkoxy, halo or C6 4aryl. Representative examples of the preparation of diaminodiphosphine ligands are 30 found in Li, Y-Y. et al., Journal of Molecular Catalysis A; Chemical, 2004, 218, 153 156. Exemplary PNNP ligands include: ANqMEDED SHEET WO 2009/055912 PCT/CA2008/001905 15 N" HN PAr 2 Ar 2 P/ wherein Ar is phenyl (abbreviated as DPPcydn), tolyl (abbreviated as di(p tolyl)PPcydn) or xylyl (abbreviated as di(3,5xylyl)PPcydn); 5 Ph Ph N N C / PPh 2 Ph 2 / \ abbreviated as dpenPPh 2

N

2 , and each optical isomer thereof and mixtures of optical isomers, 10 In another embodiment of the disclosure, N 2 is a bidentate diamine ligand of the Formula (X):

RI'R"'N-Q-NRR

2 (X) 15 wherein R", R", R20 and R21 are independently as defined for RW1 and R" and Q' is as defined for Q 1 , or one of R 8 or 119 and/or R20 or R 2 are joined with a substituent on Q6 to form, together with the nitrogen atom to which R", R", R or R' is attached, a 4- to 10-membered saturated, unsaturated or aromatic, monocyclic or bicyclic, substituted or unsubstituted ring system, where if the nitrogen atom is part of 20 aromatic ring or is bonded to an adjacent atom via a double bond, the other of R8 or R9 and/or R20 or R2 is non-existent. In embodiments of the disclosure, R18, R19, R20 and R21 are all H and Q 6 is selected from unsubstituted or substituted C-Csalkenylene where the substituents on Q6 are independently selected from one to four of CI 6 alkyl, fluoro-substituted C, 6 alkyl, halo, C.

6 alkoxy, fluoro-substituted C,.

6 alkoxy and 25 unsubstituted or substituted phenyl and/or two substituents on Q6 are joined together to form, including the carbon atoms to which they are attached, one or more WO 2009/055912 PCT/CA2008/001905 16 unsubstituted or substituted phenyl, naphthyl or ferrocenyl ring systems, and Q 6 is chiral or achiral. In a further embodiment, one of R18 or R19 or R20 or R21 are joined with a substituent on Q' to form, together with the nitrogen atom to which R", R'9, R(20 or R 2 ' is attached, a substituted or unsubstituted pyridine ring and the other of one 5 of R" or R" and/or R20 or R21 is not present. Unless otherwise specified, the term substituted means that one or more, including all, but suitably one to five, of the available hydrogen atoms on a group are replaced with C,.alkyl, fluoro-substituted

C

1 salkyl, CI- 6 alkoxy, fluoro-substituted Ci.

6 alkoxy, halo or C6.14aryl. Examples of the diamine ligands include, for example, methylenediamine, ethylenediamine, 1,2 10 diaminopropane, 1,3-diaminopropane, 1,4-diaminobutane, 2,3-diaminobutane, 1,2 cyclopentanediamine, 1,2-cyclohexanediamine, 1,1-diphenylethylenediamine, 1,1 di(p-methoxyphenyl)ethylenediamine, 1,1-di(3,5-dimethoxyphenyl)ethylenediamine, and 1,1-dinaphthylethylenediamine. Optically active diamine compounds may be also used. Examples thereof include, for example, each optical isomer of 1,2 15 diphenylethylenediamine (abbreviated name: DPEN), 1,2-di(p methoxyphenyl)ethylenediamine, 1,2-cyclohexanediamine, 1,2-cycloheptanediamine, 2,3-dimethylbutanediamine, 1-methyl-2,2-diphenylethylenediamine (abbreviated as DACH or CYDN), 1-isobutyl-2,2-diphenylethylenediamine, 1-isopropyl-2,2 diphenylethylenediamine, 1-benzyl-2,2-diphenylethylen-ediamine, 1-methyl-2,2-di(p 20 methoxyphenyl)ethylenediamine (abbreviated name: DAMEN), 1-isobutyl-2,2-di(p methoxyphenyl)-ethylenediamine (abbreviated name: DAIBEN), 1-isopropyl-2,2 di(p-methoxyphenyl)ethylenediamine (abbreviated name: DAIPEN), 1-benzyl-2,2 di(p-methoxyphenyl)ethylenediamine, I -methyl-2,2-di(3,5 dimethoxyphenyl)ethylenediamine, 1 -isopropyl-2,2-di(3,5 25 dimethoxyphenyl)ethylenediamine, I -isobutyl-2,2-di(3,5-dimethoxy phenyl)ethylenediamine, 1-benzyl-2,2-di(3,5-dimethoxyphenyl)ethylenediamine, 1 methyl-2,2-dinaphthylethylenediamine, 1-isobutyl-2,2-dinaphthylethylene- diamine, I -isopropyl-2,2-dinaphthylethylenediamine, and 1-benzyl-2,2 dinaphthylethylenediamine, and mixtures of optical isomers in any ratio. Further, 30 optically active diamine compounds which can be used are not limited to the abovementioned optically active ethylenediamine derivatives, Optically active propanediamine, butanediamine and cyclohexanediamine derivatives may be also WO 2009/055912 PCT/CA2008/001905 17 used. In addition, these diamine ligands may be prepared by the process starting from a-amino acids described in the literature (Burrows, C. J., et al., Tetrahedron Letters, 34(12), pp. 1905-1908 (1993)), or by a variety of processes described in the general remark (T. Le Gall, C. Mioskowski, and D. Lucet, Angew. Chem. Int. Ed., 37, pp. 5 2580-2627 (1998)). In another embodiment of the disclosure, N 2 is the bidentate aminopyridine ligand: Rf N R*

NH

2 wherein R' is H, Cisalkyl, fluoro-substituted CI- 6 aIkyl or C6.l 4 aryl, Rf is H, halo, C 1 . 10 6 alkyl, fluoro-substituted-CI6alkyl, C 2 -6alkenyl, C2.6alkynyl, C 3

.

7 cycloalkyl, C 1 . 6 alkoxy, fluoro-substituted-CI 6 alkoxy or C 6

-

14 aryl, and including each optical isomer thereof and mixtures of optical isomers. In another embodiment, RI is H, halo, C 1 . 4 alkyl, fluoro-substituted-C, 4 alkyl, C 24 alkenyl, C 2 .4alkynyl, C 3

.

7 cycloalkyl, C 1 4 alkoxy, fluoro-substituted-C, 4 alkoxy or phenyl. 15 In an embodiment of the disclosure, X is any suitable anionic ligand, including, but not limited to, halo, C 1

.

6 alkoxy, carboxylate, sulfonates and nitrates. Suitably X is Cl. LB is any suitable neutral Lewis base, for example any neutral two electron donor, for example acetonitrile, DMF, pyridine, tetrahydrofuran (THF), CO, 20 tBuCN or t-BuNC. Y is any non-coordinating counter anion, including, but not limited to, OTf, BF 4 , PF 6 , B(Cjsalkyl) 4 , B(fluoro-substituted-C 6 alkyl) 4 or B(C 6 -isaryl) 4 wherein C5.isaryl is unsubstituted or substituted 1-5 times with fluoro, Cl 4 alkyl or fluoro substituted C 14 alkyl. In another embodiment, Y is 25 (Rg)x- -(R).

WO 2009/055912 PCT/CA2008/001905 18 wherein RE is independently halo, C 1 4 alkyl, fluoro-substituted-C, 4 alkyl or C6- 18 aryl and x and x' are independently an integer between 1 and 4. In another embodiment, RE is halo, suitably fluoro. In a further embodiment, Y is (Rh)4 -(R. (Rh)y- 1 5 ( Nh AhA wherein Rh is independently halo, Cr 4 alkyl, fluoro-substituted-Cj 4 alkyl or C6- 1 8 aryl and y and y' are independently an integer between I and 6. In another embodiment, R" is halo, suitably fluoro. In another embodiment, Y is Al(Cj.6alky)4, Al(fluoro 10 substituted-Ci-alkyl)4, AI(C 6 -8saryl)4, AI(-O-Cs 6 alkyl) 4 , A](-O-fluoro-substituted-C 6 alkyl) 4 or Al(-O-C6.

1 saryl) 4 , wherein C&.saryl is unsubstituted or substituted 1-5 times with halo, C, 4 alkyl or fluoro-substituted Ci 4 alkyl. In afurther embodiment, Y is a carborane or a bromocarborane anion. In another embodiment, the carborane anion is a carborane such as CB1H12. In another embodiment, the bromocarborane is 15 a bromocarborane such as CBuH 6 Br 6 . In a further embodiment, Y is a phosphate anion. In a further embodiment the phosphate anion is of the formula 0 0 RJ 0 0 RJ \ / \ / 20 wherein R and R are independently selected from halo, C, 4 alkyl, fluoro-substituted

C

1

.

4 alkyl or C6-isaryl. In an embodiment, the anion Y is a chiral compound and is optically pure.

WO 2009/055912 PCT/CA2008/001905 19 In general, one or two anionic ligands bound to the neutral metal precursor is abstracted by treatment with a salt of a non-coordinating anion (i.e. one which does not formally bond to or share electrons with the metal centre in a typical covalent bond) suitably in an inert atmosphere at ambient or room temperature. This 5 leads to the formation of a salt complex comprised of a formally cationic metal complex and the associated, non- or weakly coordinating anion(s). Exemplified below (Scheme 1, reaction 1) is the use of dichloride ruthenium precursor complexes however this methodology is easily extended to other, non-chloride and other metal containing precursors. Indeed, any other halide precursor can be handled analogously 10 while similar procedures can be employed for non-halide precursors such as carboxylates, sulfonates, nitrates etc. Exposure of the resulting cationic complexes to coordinating Lewis Bases, either during the anion abstraction/metathesis reaction or by treatment of the isolated salts, leads to the formation of a coordinatively-saturated metal adduct. In an embodiment, after formation of the cationic catalysts, adducts are 15 formed by the addition of co-ordinating Lewis Bases. This is described in general terms below in reaction 2. The corresponding dicationic complexes (i.e. where both anionic ligands are removed) function in a similar manner. Scheme 1 20 L' L3 + M'Y M'X2 L [Y) L{ L4 LI L4

X

2 Lj. L3 + M'Y LB Li xL( Lfr L 4 -M'X 2 Lf'L4 rye (2) X, can be any anionic ligand (n I I or 2) L. can be any neutral ligand (typically phosphine or amine) M can be any metal Y can be any non-coordinating anion LB (i.e. Lewis Base) can be any neutral two electron donor WO 2009/055912 PCT/CA2008/001905 20 In another embodiment, the formation of the compounds of the disclosure is via a procedure wherein a precursor to the neutral complexes, is first rendered cationic or dicationic by treatment with one or two equivalents of a salt of a non-coordinating anion and then treated with the appropriate ligand to generate the 5 compounds of the disclosure, Also, a one-pot procedure can also be envisioned where all of the components are combined to generate the cationic transition-metal complexes. Accordingly, the present disclosure further includes a process for preparing a compound of the disclosure comprising combining a compound of the 10 formula

M(P

2

)(PN)X

2 (XI)

M(PN)

2

X

2 (XII) M(P)m(N 2

)X

2 (XIII) 15 M(PNNP)X 2 (XIV) or

M(P

2

)(N

2

)X

2 (XV) wherein M, P 2 , PN, P, PNNP, P 2 and X are as defined above, with one or two molar equivalents of an anion abstracting agent and optionally a non- or weakly 20 coordinating Lewis Base, and reacting under conditions to form the compound of the disclosure and optionally isolating the compound of the disclosure. In a further embodiment of the present disclosure, there is included a process for preparing a compound of the disclosure comprising combining a precursor metal compound with one or two molar equivalents of an anion abstracting agent, and 25 optionally a Lewis Base and reacting under conditions to form a cationic or dicationic precursor metal compound and combining the cationic or dicationic precursor metal compound with one or more P, P 2 , N 2 , PN, or PNNP ligands, as defined above, under conditions to form the compound of the disclosure and optionally isolating the compound of the disclosure. 30 In an embodiment of the disclosure, the precursor metal compound is of the formula [MX 2 (p-ligand)]2 or MX 2 (ligand) wherein M and X are as defined for the compounds of the disclosure and ligand is any displaceable ligand, for example, p- WO 2009/055912 PCT/CA2008/001905 21 cymene, benzene, cyclooctadiene (COD) or norbomadiene (NBD), suitably p-cymene or norbornadiene (NBD), for example [MCl2(p-eymene)] 2 or [MC1 2 (NBD)], wherein M is a metal selected from Fe, Ru and Os, in particular ruthenium. In another embodiment of the disclosure, the precursor metal 5 compound is of the formula MX 2

(P

2 )(LB),, wherein M, X, P 2 and LB are as defined above and n is I or 2. In an embodiment, the precursor metal compound is readily converted into its cationic counterparts [MX(P2)(LB)]Y or [M(P 2

)(LB)]Y

2 , by treatment with one or two molar equivalents of an anion abstracting agent as defined above. The corresponding cation is an air stable solid which is isolated in high yields 10 and stored under ambient conditions. A cationic compound of the formula

[MX(P

2 )(LB)]Y or [M(P2)(LB),]Y 2 is readily converted into the cationic catalysts of the present disclosure, for example, by reaction with one or more P 2 , N 2 or PN ligands, as defined above. In an embodiment, (P 2 ) is BINAP and LB is DMF or pyridine. Metal-diphosphine-DMF complexes have been reported in the literature 15 (Noyori et al. Tetrahedron Lett. 1991, 32:4163). In another embodiment, the anion abstracting agent is a salt of a non coordinating counter anion Y as defined above. In yet another embodiment, the ligands are selected from one or more of a compound of the Formula (VI), (VII), (VIII), (IX) and (X) as defined above. In another embodiment, the conditions to form 20 the compound of the disclosure comprise reacting at a temperature of about 20"C to about 200 "C, suitably about 50 *C to about 100 "C in a suitable solvent, for about 30 minutes to 48 hours, following by cooling to room temperature. in an embodiment of the disclosure, the compound of the disclosure is isolated using standard techniques, such as by filtration, evaporation of the solvent, recrystallization and/or 25 chromatography, to provide the compound of Formula (I), (II), (III), (IV) or (V). (III) PROCESSES UTILIZING THE COMPOUNDS OF T HE DISCLOSURE The compounds of the present disclosure are useful as catalysts in organic synthesis transformations. Accordingly, the present disclosure also includes a 30 method for catalyzing a synthetic organic reaction comprising combining starting materials for the reaction with a compound according to the disclosure under conditions for performing the reaction.

WO 2009/055912 PCT/CA2008/001905 22 The present disclosure also includes the use of a compound of the disclosure for catalyzing a synthetic organic reaction. In an embodiment of the disclosure, the synthetic organic reaction is selected from hydrogenation, transfer hydrogenation, hydroformylation, 5 hydrosilylation, hydroboration, hydroamination, hydrovinylation, hydroarylation, hydration, oxidation, epoxidation, reduction, C-C and C-X bond formation (including for example, Heck, Suzuki-Miyaura, Negishi, Buchwald-Hartwig Amination, a Ketone Arylation, N-Aryl Amination, Murahashi, Kumada, Negishi and Stille reactions), functional group interconversion, kinetic resolution, dynamic kinetic 10 resolution, cycloaddition, Diels-Alder, retro-Diels-Alder, sigmatropic rearrangement, electrocyclic reactiona, ring-opening and/or ring-closing olefin metathesis, carbonylation and aziridination. The reaction conditions for these synthetic transformation are well known to those skilled in the art. In one particular embodiment of the present disclosure, the compounds 15 of the present disclosure are competent hydrogenation (including transfer hydrogenation) catalysts (as can be seen from the tables of experimental data included herein). The complexes are air and moisture stable. Solutions can be prepared and handled in air with no obvious signs of decay. The activity of the cationic complexes matches that of the neutral precursors. In several cases, the cationic derivatives give 20 products with improved enantiomeric excess relative to the neutral congener (compare entry 27 to 28 and 29 and entry 30 to 31 and 32 in Table 1). While not wishing to be limited by theory, this is likely due to the fact that the cationic complexes disclosed herein are more reliably and reproducibly activated prior to entering the catalytic cycle. That is to say that while all of the complexes are subject 25 to activation, the cationic complexes fare better in this process than the neutral analogues. The activation process, which is carried out in alcohol solvents and is often irreproducible and unpredictable, is better suited to the cationic complexes since they are soluble in the solvent system while the neutral complexes less so. The poor solubility of the neutral compounds means that the activation is often incomplete and 30 can lead to side reactions giving catalytically inactive species or active species which do not retain the desired stereoselectivity.

WO 2009/055912 PCT/CA2008/001905 23 An interesting result to come out of the derivatization to charged species is in the ligand rearrangement observed in the solid state structure of [RuCI(pyridine)(R-binap)(R,R-cydn)]BF 4 videoe infra). The X-ray crystal structure of this compound shows that one of the P atoms of the BINAP ligand is trans to the 5 coordinated pyridine ligand (Figure 1). (It is believed that this is occurs even in the absence of a Lewis base). This is in contrast to the precursor, RuCI 2 (R-binap)(RR cydn), where both P atoms are trans to the N atoms of the diamine ligand. Such ligand rearrangements are believed to be important processes during activation of the catalysts and may account for superior activity and selectivity of the cationic catalysts 10 relative to their neutral analogues. Accordingly, the present disclosure relates to a process for the reduction of compounds comprising a carbon-carbon (C=C), carbon-oxygen (C=0) or carbon-nitrogen (C=N) double bond, to the corresponding hydrogenated alkane, alcohol or amine, comprising contacting a compound comprising the C=C, C=O or 15 C=N double bond with a catalyst of the Formula (I), (II), (III), (IV) or (V) under hydrogenation conditions. The compound comprising a C=C, C=O or C=N, includes compounds having one or more C=C, C=O and/or C=N bonds. In an embodiment of the invention, the compound comprising a 20 carbon-oxygen (C=0) or carbon-nitrogen (C=N) double bond is a compound of Formula (XI): Z R2 R23 (XI) 25 wherein, Z is selected from CR 4

R

2 , NR", (NR 2 6

R

2 )*D and 0; R 22 and R 2 3 are simultaneously or independently selected from H, aryl, CI20alkyl, C 2 . 2oalkenyl, C 3 2 ocycloalkyl and heteroaryl, said latter 5 groups being optionally substituted; WO 2009/055912 PCT/CA2008/001905 24

R

24 to R7 are independently or simultaneously selected from H, OH, C 1 20alkoxy, aryloxy, Cl2aalkyl,

C

2- 2 oalkenyl, CJ2acycloalkyl and aryl, said latter 6 groups being optionally substituted; or 5 one or more of R2 to R27 are linked to form, together with the atoms to which they are attached, an optionally substituted ring system; and D- represents a counteranion, wherein heteroaryl is a mono- or bicyclic heteroaromatic group containing from 5 to 10 atoms, of which 1-3 atoms is a heteroatom selected from the group consisting of S, 10 0 and N, and wherein the optional substituents are selected from the group consisting of halo, OH, NH 2 , OR , NR 2 2 or R" groups, in which R2 is selected from C.

6 alkyl, C2-alkenyl and aryl and one or more of the carbon atoms in the alkyl, alkenyl and cycloalkyl groups may be optionally replaced with a heteromoiety selected from 0, S, N, NH and NC1Aalkyl. 15 Reduction of compounds of Formula (XI) using a compound of the disclosure according to the process described above provides the corresponding hydrogenated compounds of Formula (XII): H Ii H Z

R

22 R2 (XII) 20 wherein Z, R22 and R23 are defined as in Formula (XII). Since R22 and R23 may be different, it is hereby understood that the final product of Formula (XII), may be chiral, thus possibly consisting of a practically pure enantiomer or of a mixture of stereoisomers, depending on the nature of the 25 catalyst used in the process. In an embodiment of the disclosure, the hydrogenation conditions characterizing the above process may comprise a base. Said base can be the substrate itself, if the latter is basic, or any conventional base. One can cite, as non-limiting examples, organic non-coordinating bases such as DBU, an alkaline or alkaline-earth WO 2009/055912 PCTCA2008/001905 25 metal carbonate, a carboxylate salt such as sodium or potassium acetate, or an alcoholate or hydroxide salt. In an embodiment of the disclosure, the bases are the alcoholate or hydroxide salts selected from the group consisting of the compounds of formula (R 30 0) 2 M' and R 3 OM", wherein M' is an alkaline-earth metal, M" is an 5 alkaline metal and R 3 0 stands for hydrogen or a linear or branched C120alkyl group. Standard hydrogenation conditions, as used herein, typically implies the mixture of the substrate with a metal complex of Formula (I), (II), (III), (IV) or (V) with or without a base, possibly in the presence of a solvent, and then treating such a mixture with a hydrogen donor solvent at a chosen pressure and temperature 10 (transfer hydrogenation) or in an atmosphere of hydrogen gas at a chosen pressure and temperature. Varying the reaction conditions, including for example, temperature, pressure, solvent and reagent ratios, to optimize the yield of the desired product would be well within the abilities of a person skilled in the art. The following non-limiting examples are illustrative of the present 15 disclosure: EXAMPLES The disclosure will now be described in further details by way of the following examples, wherein the temperatures are indicated in degrees centigrade and the abbreviations have the usual meaning in the art. All the procedures described 20 hereafter have been carried out under an inert atmosphere unless stated otherwise. All preparations and manipulations were carried out under H2, N 2 or Ar atmospheres with the use of standard Schlenk, vacuum line and glove box techniques in dry, oxygen free solvents. Tetrahydrofuran (THF), diethyl ether (Et 2 O), methylene chloride and hexanes were obtained using an IT solvent purification system. Deuterated solvents 25 were degassed and dried over activated molecular sieves. NMR spectra were recorded on a 300 MHz spectrometer (300 MHz for 'H, 75 MHz for "C and 121.5 for "P). All 31 P chemical shifts were measured relative to 85% H 3

PO

4 as an external reference. 'H and 1C chemical shifts were measured relative to partially deuterated solvent peaks but are reported relative to tetramethylsilane. 30 Example 1: Synthesis of Cationic Ruthenium Precursors. (a) [RuCI(p-cymene)] 2 [BF42 WO 2009/055912 PCTICA2008/001905 26 In an Ar filled flask, 0.25 g (0.041 mmol) [RuCl2(p-cymene)]2 and 0.16 g (0.082 mmol) of AgBF 4 were combined. CH 2 0 2 (10 mL) was added and the resulting orange suspension was left to stir at ambient temperature. Within several minutes the suspension darkened to brown/green in colour. After 2 hours, the 5 suspension was filtered through Celite and the orange filtrate was reduced to approximately 1 mL in volume. Addition of hexane afforded an oily orange solid which was washed repeatedly with hexane and dried in vacuo. Yield: 0.215 g (74 %). Example 2: Synthesis ofCationic Ruthenium Hydrogenation Catalysts 10 (a) [RuCl(R-binap)(R,R-cydn)]BF 4 In an Ar filled flask, 0.600 g (0.66 mmol) of RuCl 2 (R-binap)(R,R cydn) and 0.129 g (0.66 mmol) of AgBF 4 were combined. CH 2

CJ

2 (15 mL) was added and the resulting rust coloured suspension was left to stir at ambient temperature for two hours after which time it was filtered, in air, through Celite. The orange filtrate 15 was reduced to dryness leaving an orange residue. Yield: 0.620 g (97 %). "P NMR (ppm, CDCb3): 7.53 (d, Jpp = 45 Hz), 67.5 (d, Jp = 45 Hz). Ph 2 Ci H 2 O r o P P h 2 N N/ 20 (b) [RuCJ(R-binap)(Ph2PCH 2 CH2NH)]BF 4 In an Ar filled flask, 0.766 g (0.73 mmol) of RuCl 2

(R

binap)(Ph2PCH 2 CHzNHz) and 0.143 g (0.73 mmol) of AgBF 4 were combined. CH2C 2 (15 mL) was added and the resulting dark orange suspension was left to stir at ambient temperature for two hours after which time it was filtered, in air, through 25 Celite. The dark orange filtrate was reduced to dryness leaving a deep orange residue. Yield: 0.790 g (98 %). 31 P NMR (ppm, CDCb): 32.6 (dd, JPP = 31 Hz, JPP = 24 Hz), 48.0 (dd, Jpp = 34 Hz, Jpp = 31 Hz), 62.7 (dd, Jpp = 34 Hz, Jpp = 24 Hz).

WO 2009/055912 PCT/CA2008/001905 27 Ph2 C1 H2 P z N P P Ph 2 Ph 2 (c) [RuCI(Ph 2

PCH

2

CH

2

AH

2 )2jBF 4 5 In an Ar filled flask, 0.750 g (1.19 mmol) of RuCl2(Ph 2

PCH

2

CH

2 NH2)2 and 0.232 g (1.19 mmol) of AgBF 4 were combined.

CH

2

C

2 (15 mL) was added and the resulting red suspension was left to stir at ambient temperature for two hours after which time it was filtered, in air, through Celite. The dark red filtrate was reduced to dryness leaving a deep red residue. Yield: 0.790 g (97 10 %). 3 P NMR (ppm, acetone-D 6 ): 55.0 (d, Jpp = 36 Hz), 73.3 (d, Jpp= 36 Hz). H2 C1 l 2 PPh 2 Ph2 N/0 Ru %N H2N 1 Ru ICIj R NH 2 P P OR Ph2P* vClv j PPh 2 Ph 2 BF, Ph 2 H2 H2N 2[BF4] (d) [RuCl(MeCN)(R-binap)(R, R-cydn)]BF 4 15 In an Ar filled flask, 0.150 g (0.16 mmol) of [RuCl(R-binap)(R,R cydn)]BF 4 was dissolved in 6 mL of CH 2 C1 2 and 41 mL (0.78 mmol) of MeCN was added and the brown solution was left to stir. After 16 hours the solution had changed to pale green in colour. Removal of an aliquot for subsequent 31 P NMR analysis showed that no starting material remained. Concentration of the solvent to 20 approximately 1 mL followed by the addition of hexane (10 mL) afforded a pale green solid. The solid was filtered off, washed with bexane (2 x 5 mL) and dried in vacuo. Yield: 0.127 g (81 %). NMR analysis of the isolated solid revealed the WO 2009/055912 PCT/CA2008/001905 28 presence of several isomeric species, the major constituent accounting for 80 % of the integrated intensity. NMR data are given only for the major isomer. "P NMR (ppm, CDCb): 46,3 (d, Jpp = 34 Hz), 48.8 (d, Jpp = 34 Hz). Ph C1 H2 Ph 2 N 21-1 -eBF4 5 (e) [RuC/(pyridine)(R-binap)(R, R-cydn)]BF 4 In an Ar filled flask, 0.150 g (0.16 mmol) of [RuCl(R-binap)(R,R cydn)JBF 4 was dissolved in 6 mL of CH 2

CI

2 and 63 mL (0.78 mmol) of pyridine was added and the brown solution was left to stir. After 16 hours the solution had changed to yellow in colour. Removal of an aliquot for subsequent 3P NMR analysis showed 10 that no starting material remained. Concentration of the solvent to approximately I mL followed by the addition of hexane (10 mL) afforded a yellow solid. The solid was filtered off, washed with hexane (2 x 5 mL) and dried in vacuo Yield: 0.152 g (94 %). NMR analysis of the isolated solid revealed two complexes; one identified as the desired product (NMR data given below) and the other as starting material (see 15 above). The two compounds were present in approximately equal amounts. It is unclear if a single product is isolated and dissociation of bound pyridine occurs upon dissolution or if reversion to starting material occurs during isolation. "P NMR (ppm,

CDC

3 ): 55.2 (d, Jpp = 37 Hz), 49.4 (d, Jpp = 37 Hz). PN N H 2 20 N () [RuC(R-binap)(SS-Ph 2 PCH(Ph)CHM(Ph)NH2)]BF 4 WO 2009/055912 PCT/CA2008/001905 29 In an Ar filled flask, 0,150 g (0.13 mmol) of RuCI 2 (R-binap)(S,S Ph 2 PCH(Ph)CH(Ph)NH 2 ) and 0.025 g (0.13 mmol) of AgBF 4 were combined. CH2C2 (6 mL) was added and the resulting green suspension was left to stir at ambient temperature for sixteen hours over which time it changed to brown in colour. The 5 suspension was filtered, in air, through Celite and the brown filtrate was reduced to dryness leaving a brown residue. Yield: 0.108 g (69 %). "P NMR (ppm, CD 2

C

2 ): 34.5 (pseudo t, Jpp = 27 Hz), 44.5 (dd, Jpp = 31 Hz, Jpp = 28 Hz), 83.9 (dd, Jpp = 31 Hz, Jpp = 26 Hz). Ph 2 C1 H 2 Ph PPh 2 Ph 2 Ph 10 GBF4 10 0 P (g) [RuCI(S-binap)(SS-Ph2PCH(Ph)CH(Ph)NH2)]BF 4 In an Ar filled flask, 0.150 g (0.13 mmol) of RuCI 2 (S-binap)(S,S Ph 2 PCH(Ph)CH(Ph)NH 2 ) and 0.025 g (0.13 mmol) of AgBF 4 were combined. CH 2 C12 15 (6 mL) was added and the resulting green suspension was left to stir at ambient temperature for sixteen hours over which time it changed to brown in colour. The suspension was filtered, in air, through Celite and the brown filtrate was reduced to dryness leaving a brown residue. Yield: 0.096 g (61 %). "P NMR (ppm, CD 2 Cl2): 26.7 (dd, Jpp = 27 Hz, Jpp = 20 Hz), 48.5 (dd, Jpp = 33 Hz, Jpp = 27 Hz), 86.3 (dd, Jpp = 20 33 Hz, Jpp = 20 Hz), WO 2009/055912 PCT/CA2008/001905 30 Ph 2 C1 A2 Ph SRut P.N PPh2 h 2 Ph (h) [RuCI(R-binap)(R, R-cydn)][B(C6Fs)4] In an Ar filled flask, 0.200 g (0.22 mmol) of RuCI 2 (R-binap)(R,R 5 cydn) and 0.192 g (0.22 mmol) of [Li(OEtz) 2

.,][B(C

6

F)

4 ] were combined. CH 2

CI

2 (10 mL) was added and the resulting dark orange suspension was left to stir at ambient temperature for 16 hours after which time it was filtered, in air, through Celite, The orange filtrate was reduced to dryness leaving an orange residue. Yield: 0.247 g (72 %). 3 P NMR (ppm, CDC 3 ): 13.1 (d, Jpp = 46 Hz), 72.6 (d, JPP 46 Hz). 10 Ph, C1 H2 N PI~h 2 H 2 (1) [RuCl(R-binap)(Ph 2

PCH

2

CH

2 NH)][B(CF) 4] 15 In an Ar filled flask, 0.200 g (0.20 mmol) of RuCl 2

(R

binap)(Ph 2

PCH

2

CH

2

NH

2 ) and 0.170 g (0.20 mmol) of [Li(OEt 2

)

2

,

5

][B(C

6

FS)

4 ] were combined. CH 2

CI

2 (10 mL) was added and the resulting dark orange suspension was left to stir at ambient temperature for sixteen hours after which time it was filtered, in air, through Celite. The dark orange filtrate was reduced to dryness leaving a deep 20 orange residue. Yield: 0.273 g (84 %). 3 1 P NMR (ppm, CD2Cl 2 ): 31.3 (dd, Jpp = 31 Hz, Jpp = 24 Hz), 48.0 (dd, Jpp = 35 Hz, Jpp = 31 Hz), 62.2 (dd, Jpp = 35 Hz, Jpp = 24 Hz), WO 2009/055912 PCT/CA2008/001905 31 Ph 2 C1 H2 Ph 2 Ph 2 DB(C6F5)4 () [RuCl(Ph2PCH 2

CH

2 NH2)2][B(C 6 Fs)4] 5 In an Ar filled flask, 0.200 g (0.32 mmol) of RuCl 2 (Ph 2

PCH

2

CH

2

NH

2 )2 and 0.276 g (0.32 mmol) of {Li(OEt 2

)

2 ,5][B(C 6 F5) 4 ] were combined. CH 2 Cl 2 (10 mL) was added and the resulting orange suspension was left to stir at ambient temperature for sixteen hours after which time it was filtered, in air, through Celite. The orange filtrate was reduced to dryness leaving a deep orange 10 residue. Yield: 0.273 g (86 %). "P NMR (ppm, acetone-D6): 54.9 (d, Jpp = 36 Hz), 72.7 (d, Jpp = 36 Hz). H2 C1 H2 PPh 2 Ph 2 P N/111Ru1 N H2N n C tr,' R NH2 2R 'Ru' 'R -I 2 p pOR Ph2P* CPPh 2 Ph 2 Ph 2

NH

2 H2N 2 [B(C 6

F

5

)

4 ] 15 (k) [RuCl(R-tolbinap)(R, R-Ph 2 PCH(Ph)CH(CH3)NH2)]BF 4 In an Ar filled flask, 0.150 g (0.13 mmol) of RuCl 2 (R-tolbinap)(R,R Ph 2 PCH(Ph)CH(Me)NH 2 ) and 0.025 g (0.13 mmol) of AgBF 4 were combined.

CH

2

C

2 (10 mL) was added and the resulting brown suspension was left to stir at ambient temperature for 2 hours. The suspension was then filtered, in air, through 20 Celite and the brown filtrate was reduced to dryness leaving a brown residue. Yield: WO 2009/055912 PCT/CA2008/001905 32 0.112 g (72 %). "P NMR (ppm, CD 2

CI

2 ): 25.3 (br m), 48.6 (br t, Jpp 30 Hz), 87.6 (dd, Jpp = 30 Hz, Jpp= 20 Hz).

BF

4 p N S C Ph 2 5 (1) [RuCl(R-tolbinap)(R, R-Ph 2 PCH(Ph)CH(CH)NHd][B(C6Fs)4] In an Ar filled flask, 0.100 g (0.085 mmol) of RuC]2(R-tolbinap)(R,R Ph 2 PCH(Ph)CH(Me)NH 2 ) and 0.074 g (0.085 mmol) of [Li(OEt 2

)

2 5

][B(C

6

F

5

)

4 ] were combined. CH 2 C1 2 (10 mL) was added and the resulting brown suspension was left to 10 stir at ambient temperature for 2 hours. The suspension was then filtered, in air, through Celite and the brown filtrate was reduced to dryness leaving a brown residue. Yield: 0.123 g (79 %). "P NMR (ppm, CD 2 Cl2): 25.3 (br m), 48.4 (br t, Jpp= 30 Hz), 87.7 (dd, Jpp = 30 Hz, Jpp = 20 Hz). S (C6F5)4 N N H 2 p 9,N Cl Ph 2 15 WO 2009/055912 PCT/CA2008/001905 33 (m) [RuCI(R-3,5-xylylbinap)(R, R-Ph 2 PCH(Ph)CH(CHs)NH2)]BF 4 3P NMR (ppm, CD2Cl 2 ): 31.6 (br m), 46.3 (br t, Jpp = 32 Hz), 89.4 (br M).

BF

4

H

2 p N -C hz NN, I / 5 (n) [RuCl(R-3,5-xylylbinap)(R, R-Ph 2 PCH(Ph)CH(CH3)NH)]L[B(C 6 F)41 3 'P NMR (ppm, CD2C12): 31.6 (br m), 46.3 (br m), 89,4 (dd, Jpp 33 Hz, Jpp = 28 Hz). 10 OB(C6F5)4 H2 N N C Ph 2 (o) [RuCi(NH 2

CH

2 Py)(PPh 3 )2BF 4 "P NMR (ppm, CD 2 Cl 2 ): 14.2 (br), 38.4 (br m), 56.6 (br m). 15 Ph 3 P' Ru Ph 2 P'CN H2 BF4 C1 2 WO 2009/055912 PCT/CA2008/001905 34 (p) [RuC(NH 2

CJH

2 Py)(PPh 3 )2][B(C 6 Fs) 4 ] 3 P NMR (ppm, CD 2

CI

2 ): 38.8 (d, Jpp = 27 Hz), 41.0 (br), 55.4 (d, Jpe= 27 Hz), 5 Ph 3 P, RU' Ph P 1 BN(C6F)4 (q) [RuCI(R-binap)(Sc, Rp-(NH 2 CH(CHs)-Fc-PPh2))]BF4 P NMR (ppm, CD 2 Cl2): 42.4 (br m), 54.5 (br). 10 1BF 4 P Ru, S Cl Ph Fe (r) [RuCJ(R-binap)(Rc, Sp-(NH 2 CH(CH)-Fc-PPh))]BF 4 3 P NMR (ppm, CD2C2): No resolved peaks at ambient temperature. 15 2BF4 PH N. N. N -l Ph 2 Fe WO 2009/055912 PCT/CA2008/001905 35 (s) [RuCl(R-binap)(Sc, Rp-(NH2CH(CH 3 )-Fc-PPh))][B(C6Fs) 4 ] "P NMR (ppm, CD 2 Cl2): 42.7 (br m), 55.1 (br m). B(C6F5)4 NN -N

P

~Ru, C' Ph 2 5 () [RuC4(R-binap)(Rc, Sp-(NtH2CH(CH 3 )-Fc-PPh))][B(C 6 Fs)4] 31 P NMR (ppm, CD 2 Cl 2 ): 44.0 (br), 68.0 (br). B(C6F5)4 PR 10 (u) [RuCl(R, R-DPPcydn)]BF4 3P 1 NM (ppm CD2Cl2): Several broadened peaks between 10 and 70 ppm. HN N Ru A Ar= 15 WO 2009/055912 PCT/CA2008/001905 36 (v) [RuCl(RR-DPPcydn)][B(C 6 Fs) 4 ] 31 P NMR (ppm, CD 2 Cl 2 ): Several broadened peaks between 10 and 70 ppm. PC, B(C6F5)4 HN- <NH Ar 2 Ar\ Ar= 5 (w) [RuCl(R, R-di(p-tolyl)PPcydn)]BF 4 P NMR (ppm, CD 2

CI

2 ): Several broadened peaks between 10 and 70 ppm. HN , 0

BF

4 HN INH Ru" A Ar= Ar 2 A\/ Ar / 10 (x) [RuCl(R, R-di(p-tolyl)PPcydn)][B(CFs)4] P NMR (ppm, CD 2 CI2): Several broadened peaks between 10 and 70 ppm. PC, BB(C6FS)4 HN I uNH /r ArAr 15 (y) [RuCl(R,R-di(3,5-xylyl)PPcydn)]BF 4 alP NMR (ppm, CD 2 Cl2): Several broadened peaks between 10 and 70 ppm.

WO 2009/055912 PCT/CA2008/001905 37 C 0

BF

4 HN, INH @Ru% Ar= Ar 2 Ar (z) [RuC(R, R-di(3,5-xylyl)PPcydn)][B(C 6 Fs)4] 31 P NMR (ppm, CD2CI 2 ): Several broadened peaks between 10 and 70 5 ppm. PC, B(C6F5)4 HN u INH p@PRu% Ar= Ar2 Ar\ (aa) [RuCl(S-PPhos)(S-DAIPEN)]BF 4 "P NMR (ppm, CD 2 Ci2): Several broadened peaks between 40 and 65 10 ppm. 0 O N Ph2 NJ , I N> (bb) [RuCl(S-PPhos) (S-DAIP EN)][B(CFs)4] 31 P NMR (ppm, CD 2 Cl2): Several broadened peaks between 40 and 75 15 ppm.

WO 2009/055912 PCT/CA2008/001905 38 0 N Ph 2 H OI, C. N O S/ 'N N Ph2 H2 0 9B(C6Fs)4 (cc) [RuCl(S-XylylPPhos)(S-DAIPEN)]BF 3 P NMR (ppm, CD2C1 2 ): Several broadened peaks between 40 and 65 5 ppm. 0 0 N A NJ Ar 2 H24 O0 Ar= 3,5-dmethylphenyl (dd) [RuCI(S-XylylPPhos)(S-DAIPEA)][B(CFs)4] 31 P NMR (ppm, CD 2 Cl 2 ): Several broadened peaks between 40 and 75 10 ppm. 0 No 0 O 0J 2 121 0 1 Ru 0 0 P H2 S Ar 2 B(C6F5)4 0 Ar=3,5 dimethylp henyl WO 2009/055912 PCT/CA2008/001905 39 (ee) [RuCl(S-binap)(S-DAIPEN)JBF 4 P NMR (ppm, CD 2 Cl2); Several broadened peaks between 40 and 65 ppm.

0 /N 0 p yI 2 O /D Ru., Ph 2

H

2

'BF

4 5 (ff) [RuCi(S-b/nap) (S-DA JPEN)][B(CFs)4] 3 1 P NMR (ppm, CD2Cl2): Several broadened peaks between -20 and 70 ppm. 0 Phzu - 7 "N Ph 2 2 G B(CF5)4 10 (gg) [(R-binap)RuCl(RR-dach)]PF. Ph 2 Cl H2 P N rw P~h'RuN 7 "N ~PPh N ePF6 In an Ar filled flask, 0.280 g (0.31 mmol) of RuCI 2 (R-binap)(RR 15 dach) and 0.078 g (0.31 mmol) of AgPF 6 were combined. CH 2

C

2 (15 mL) was added and the resulting brown coloured suspension was left to stir at ambient temperature WO 2009/055912 PCT/CA2008/00190 5 40 for 24 hours after which time it was filtered, in air, through a 0.45 mm PTFE syringe filter. The orange filtrate was reduced to dryness leaving an orange residue. Yield: 0.280 g (89 %). "P{'H} NMR (ppm, CDC 3 ): 7.53 (d, 2 Jpp = 45 Hz), 67.5 (d, 2 J,,= 45 Hz), 208.6 (septuplet, 2 JpF = 710 Hz). **R,R-dach = R, R-cydn 5 (hh) [(R-binap)RuC(R, R-dach)]OTf Ph 2 C1 H2 NN >p.Nt@/N' Ru pph, N 2H 'OTf In an Ar filled flask, 0.100 g (0.11 mmol) of RuCl 2 (R-binap)(RR dach) and 0.02 8 g (0,11 mmol) of AgOTf were combined. CH2C2 (5 mL) was added and the resulting rust coloured suspension was left to stir at ambient temperature for 2 10 hours after which time it was filtered, in air, through a 0.45 mm PTFE syringe filter, The orange filtrate was reduced to dryness leaving an orange residue. Yield: 0.065 g (58 %). " P ('1-) NMR (ppm, CDCL 3 ): 7.53 (d, 2 Jpp = 45 Hz), 67.5 (d, Jpp = 45 Hz).). * * R, R-dach = R, R-cydn (ii) [(R-binap)RuC(R, R-dach)][B(3,5-(CF 3 )2C6H3)4.

Ph2 C1 H2 N Ru PPh2 15 B(3,5-(CF3)2C6H3)4 In an Ar filled flask, 0.100 g (0.11 mmol) of RuCl2(R-binap)(R,R dach), 0.097 g (0.11 mmol) of Na[B(3,5-(CF 3

)

2

C

6

H

3

)

4 ] and 21 mg (0.11 mmol) of AgBF 4 were combined. CDCI, (2 mL) was added and the resulting rust coloured suspension was left to stir at ambient temperature for 18 hours after which time it was 20 filtered, in air, through a 0.45 mm PTFE syringe filter. The orange filtrate was reduced to dryness leaving a yellow-orange residue. Yield: 0.115 g (61 %). 31

P{'H}

WO 2009/055912 PCT/CA2008/001905 41 NMR (ppm, CDC 3 ): 7.73 (d, 2Jr, = 45 Hz), 67.2 (d, 2Jp= 45 Hz)). **R,R-dach = R, R-cydn (j) [(R-binap)RuCl(PGly)jPF 6 Ph C1 H2 N I Ph2 Ph 2 N,, 6

PF

6 5 In an Ar filled flask, 0.075 g (0.074 mmol) of RuC1 2

(R

binap)(Ph 2

PCH

2

CH

2

NH

2 ) and 0.019 g (0.074 mmol) of AgPF 6 were combined.

CH

2 C1 2 (5 mL) was added and the resulting dark orange suspension was left to stir at ambient temperature for 24 hours after which time it was filtered, in air, through a 0.45 mm PTFE syringe filter. The dark brown-orange filtrate was reduced to dryness 10 leaving a brown residue. Yield: 0.032 g (39 %). "P{'H} NMR (ppm, CDC 3 ): 32.6 (dd, 2 Jpp = 31 Hz, 2 Jpp = 24 Hz), 48.0 (dd, 2 Jpp = 34 Hz, 2jyi = 31 Hz), 62.7 (dd, 2 = 34 Hz, 2Jp = 24 Hz). There is also formation of another unidentified AB signal in 3'P NMR: 15.3 (d, 2 Jpp = 17 Hz), 17.3 (d, 2 Jpp = 17 Hz). **PGly = Ph 2

PCH

2

CH

2

NH

2 (kk) [(R-binap)RuC(PGly)][B(3,5-(CF 3 )2CsH 3 )4] Ph 2 Cl

H

2 P P Ru I Ph 2 Ph 2 15

-..

B(3,5-(CF 3

)

2

C

6

H

3

)

4 In an Ar filled flask, 0.08 g (0.078 mmol) of RuCI2(R binap)(Ph 2

PCH

2

CH

2 NH2), 0.069 g (0.078 mniol) of Na[B(3,5-(CF 3

)

2

C

6 H3) 4 ] and 15 mg (0.078 mmol) of AgBF 4 were combined. CH 2 Cl 2 (2 mL) was added and the resulting rust coloured suspension was left to stir at ambient temperature for 18 hours 20 after which time it was filtered, in air, through a 0.45 mm PTFE syringe filter. The orange filtrate was reduced to dryness leaving a yellow-orange residue. Yield: 0.090 g WO 2009/055912 PCT/CA2008/001905 42 (63 %). "P('H} NMR (ppm, CDC 3 ): 7.73 (d, 2 Jep = 45 Hz), 67.2 (d, 2pp= 45 Hz). **PGly = Ph 2

PCH

2

CH

2

NH

2 (11) [(R-binap)RuCl(PGly)]OTf Ph2 C' H2 P P Ph2 Ph2 0 OTf 5 In an Ar filled flask, 0.150 g (0.15 mmol) of RuCl 2 (R-binap)(PGly) and 0.038 g (0.15 mmol) of AgOTf were combined. CH 2 C1 2 (5 mL) was added and the resulting dark brown suspension was left to stir at ambient temperature for 24 hours after which time it was filtered, in air, through a 0.45 mm PTFE syringe filter. The dark brown filtrate was reduced to dryness leaving a brown-yellow residue. 10 Yield: 0.130 g (78 %). "P{ 1 H} NMR (ppm, CDCI 3 ): 29.4 (t, 2JP = 27 Hz), 45.8 (dd, 2jPP = 33 Hz), 60.5 (t, 2Jpp = 27 Hz). There is also formation of another unidentified AB signal in 3 P NMR: 13.4 (d, 2Jpp = 17 Hz), 15.4 (d, 2 Jpp = 17 Hz). **PGly = Ph 2

PCH

2

CH

2

NH

2 (mm) [RuCl(PGly)2jPF 6 CI PPh2 Ph 2 P uit H2NH 'Rj'MClu1e" 6 NH2 OR

I-

2 ;uI..'C

P

2

P

2 Ph 2 P C PPh2 Ph2

PF

6 Ph2 H2 N 15 G PF 6 12 In an Ar filled flask, 0.075 g (0.12 mmol) of RuCl2(PGly) 2 and 0.030 g (0.12 mmol) of AgPF6 were combined. CH2C12 (5 mL) was added and the resulting brown suspension was left to stir at ambient temperature for 24 hours after which time it was filtered, in air, through a 0.45 mm PTFE syringe filter. The dark orange filtrate 20 was reduced to dryness leaving a yellow brown residue. Yield: 0.030 g (35 %). "P{'H} NMR (ppm, CDC 3 ): 7 different doublets in the range 52-73 ppm. **PGly Ph 2

PCH

2

CH

2

NH

2 WO 2009/055912 PCT/CA2008/001905 43 (nn) fRuCl(PGly)2]OTf C1 PPh 2 Ph 2 P RH2N Ru", NH2 OR Ph2P 1 PPh2 Ph 2 Ph 2 -h NH2 H In an Ar filled flask, 0.150 g (0.24 mmol) of RuCl 2 (PGly) 2 and 0.061 g (0.24 mmol) of AgPF 6 were combined. CH 2 C1 2 (10 mL) was added and the resulting 5 brown suspension was left to stir at ambient temperature for 24 hours after which time it was filtered, in air, through a 0.45 mm PTFE syringe filter, The dark yellow brown filtrate was reduced to dryness leaving an orange residue. Yield: 0.095 g (53 %). "P('H} NMR (ppm, CDC1 3 ): 7 different doublets in the range 52-73 ppm. **PGly = Ph 2

PCH

2

CH

2

NH

2 10 (oo) [RuCl(PGly) 2 ][B(3,5-(CF 3 )2C 6

H)

4 ] C1 PPh 2 Ph 2 P uH2NtirD CI j, NH2 L pIw, RU...P OR R C PPh2 Ph 2 Ph 2 H2 H 2 N eB(3,5-(CF3)2C6H3)4 Ie B(3,5-(CF3)2C6H3)4 In an Ar filled flask, 0.08 g (0.13 mmol) of RuCl 2 (PGly) 2 , 0.112 g (0.13 mmol) of Na[B(3,5-(CF3) 2

C

6

H

3

)

4 ] and 25 mg (0.13 mmol) of AgBF 4 were combined. CH 2 C1 2 (2 mL) was added and the resulting rust coloured suspension was 15 left to stir at ambient temperature for 18 hours after which time it was filtered, in air, through a 0.45 mm PTFE syringe filter. The orange filtrate was reduced to dryness leaving an orange residue. Yield: 0.030 g (16 %), 6 different doublets in the range 30 51 ppm. **PGly = Ph 2

PCH

2

CH

2

NH

2 (pp) [RuCI(S-PhanePhos)(R, R-DPEN)]BF 4 WO 2009/055912 PCT/CA2008/001905 44 GBF4 . PPh 2 1Q) H 2 Ph PCI N* Ph 2

H

2 Ph In an Ar filled flask, 0.100 g (0.10 mmol) of RuCI 2 (S-PhanePhos)(RR DPEN) and 0.020 g (0.10 mmol) of AgBF 4 were combined. CH 2 CL2 (5 mL) was added and the resulting brown suspension was left to stir at ambient temperature for 5 sixteen hours. The suspension was filtered, in air, through Celite and the brown filtrate was reduced to dryness leaving a brown residue. Yield: 0.048 g (46 %). "P NMR (ppm, CD 2 Cl2): 52.0 (d, Jpp = 28 Hz), 43.1 (d, Jpp = 28 Hz). (qq) [RuC(S-PhanePhos)(R, R-DPEN)]B(C 6 Fs)4 PPh 2 KA GH 2 Ph A RuczN u N P

CNH

2 Ph 2 Ph (B(C6F5)4 10 In an Ar filled flask, 0.050 g (0.06 mmol) of RuCl 2 (S-PhanePhos)(R,R DPEN) and 0.045 g (0.06 mmol) of Li(OEt2) 2

.[B(C

6

F

5 )4] were combined. CH 2 C1 2 (5 mL) was added and the resulting brown suspension was left to stir at ambient temperature for sixteen hours. The suspension was filtered, in air, through Celite and the brown filtrate was reduced to dryness leaving a brown residue. Yield: 0.036 g (40 15 %), P NMR (ppm, CD2Cl2): 50.5 (d, Jpp = 28 Hz), 42.4 (d, Jpp = 28 Hz). (rr) [RuCl(S-XylylPhanePhos)(R, R-DPEN)]BF 4 PAr2 H2 .Ph u: N Ar = 3,5-dimethylphenyl P Cl N Ar 2

H

2 Ph 9BF4 WO 2009/055912 PCT/CA2008/001905 45 In an Ar filled flask, 0.100 g (0.10 mmol) of RuCI2(S XylylPhanePhos)(RR-DPEN) and 0.018 g (0.10 mmol) of AgBF 4 were combined.

CH

2 Cl 2 (5 mL) was added and the resulting brown suspension was left to stir at ambient temperature for sixteen hours. The suspension was filtered, in air, through 5 Celite and the brown filtrate was reduced to dryness leaving a brown residue. Yield: 0.066 g (63 %). "P NMR (ppm, CD 2 Cl 2 ): 52 (d, Jpp = 28 Hz), 42 (d, Jpp = 28 Hz). (ss) [RuCI(S-XylyPhanePhos)(R, R-DPEN)]B(C 6 F)4 PAr 2 6 H 2 ,Ph tupN Ar =3,5-dimethylphenyl Ar 2 C1 H2 NPh E)B(C6F5)4 10 In an Ar filled flask, 0.050 g (0.05 mmol) of RuC1 2 (S-PhanePhos)(RR DPEN) and 0.041 g (0.05 mmol) of Li(OEt2) 2 .s[B(C 6 Fs) 4 ] were combined. CH 2 Cl 2 (5 mL) was added and the resulting brown suspension was left to stir at ambient temperature for sixteen hours, The suspension was filtered, in air, through Celite and the brown filtrate was reduced to dryness leaving a brown residue. Yield: 0.065 g (81 15 %). 3 P NMR (ppm, CD 2

C

2 ): 52,2 (d, Jpp = 29Hz), 41.5 (d, Jpp = 29 Hz). (tt) [RuCI(PPhs)2((S)-J-(pyridin-2-yl)ethanamine)]BF4 H2 ,N PPh 3 N C1 PPh 3 9

BF

4 In an Ar filled flask, 0.100 g (0.12 mmol) of RuCl2(PPh 3

)

2 ((S)-1 (pyridin-2-yl)ethanamine) and 0.024 g (0.12 mmol) of AgBF 4 were combined. 20 CH 2 C1 2 (5 mL) was added and the resulting brown suspension was left to stir at ambient temperature for two hours. The suspension was filtered through a 0.45 pm PTFE syringe filter and the brown filtrate was reduced to dryness leaving a brown residue. Yield: 0.070 g (66 %). "F NMR (282 MHz, CD 2 C1 2 ): - 152 (s).

WO 2009/055912 PCT/CA2008/001905 46 (uu) [RuCI(S-XylylPPhos)((S)-1-(pyridin-2-yl)ethanamine)]BF 4 0 H2Cl Xy12 Ru 0 N P ' NN® Xyl 2 ' -N

GBF

4 Os In an Ar filled flask, 0.150 g (0.14 mmol) of RuCl 2 (S-XylylPPhos)((S) 5 1-(pyridin-2-yl)ethanamnine) and 0.027 g (0.14 mmol) of AgBF 4 were combined.

CH

2 C1 2 (5 mL) was added and the resulting brown suspension was left to stir at ambient temperature for two hours. The suspension was filtered through a 0.45 pm PTFE syringe filter and the brown filtrate was reduced to dryness leaving a brown residue, Yield: 0.127 g (81 %). "F NMR (282 MHz, CD 2

C

2 ): - 152 (s). 10 (vv) [RuCl(R-BINAP)((S)-1-(pyridin-2-yl)ethanamine)]BF 4 H2 Ph 2 N Cl p Ru N R PhV2

OBF

4 Ph2 In an Ar filled flask, 0.150 g (0.16 mmol) of RuCI 2 (R-BINAP)((S)-l (pyridin-2-yl)ethanamine) and 0.032 g (0.16 mmol) of AgBF 4 were combined.

CH

2

C

2 (5 mL) was added and the resulting brown suspension was left to stir at 15 ambient temperature for two hours. The suspension was filtered through a 0.45 im PTFE syringe filter and the brown filtrate was reduced to dryness leaving a brown residue. Yield: 0.087 g (55 %). "P NMR (ppm, CD 2 CI2): No resolved peaks at ambient temperature. "F NMR (282 MHz, CD 2 Cl2): - 152 (s).

WO 20091055912 PCTCA2008/001905 47 (ww) [RuC(Sc, Rp-PCyrCH(CHs)-F-PCy 2 )((S)--(pyridin-2-yl)ethanarnine)jBF 4 H N CI Cy 2 PuP Ru p-. s e N Cy 2 GBF4 In an Ar filled flask, 0.075 g (0.08 mmol) of RuCi2(Sc,Rp-PCyr CH(CH3)-Fc-PCy 2 )((S)-1-(pyridin-2-yl)ethanamine) and 0.016 g (0.08 mmol) of 5 AgBF 4 were combined. CH 2 Cl 2 (5 mL) was added and the resulting brown suspension was left to stir at ambient temperature for two hours. The suspension was filtered through a 0.45 psm PTFE syringe filter and the brown filtrate was reduced to dryness leaving a brown residue. Yield: 0.079 g (63 %). '9F NMR (282 MHz, CD2C1 2 ): - 152 (s). 10 (xx) [RuCl(R-binap)(R, R-cydn)]CBuH, 2 In the dry box, RuC1 2 (Binap)(cydn) (0.18 g, 0.19 mmol) was dissolved in CH 2 Cl 2 and Ag(CBn H1 2 ) (50 mg, 0.19 mmol) was dissolved in benzene and

CH

2

CI

2 . The two portions were then mixed and stirred for half hour. The AgCl then formed was filtered off and the compound was recrystallized from hexanes. Yield: 15 0.15 g, 74%. A Ph A Ph Ph Nu_ AgCBllH12 PN /R CBIIH1 Ph h/ /Ph Ph 31P NMR: 67,4 (d), 7.4 (d) (yy) [RuCI(R-binap)(R, R-cydn)]CB 2

H

6 Br 6 20 In the dry box, RuCl 2 (Binap)(cydn) (12,5 mg, 0.014 mmol) was dissolved in CH 2

CI

2 and Ag(CBuIH 6 Br 6 ) (10 mg, 0.014 mmol) was dissolved in benzene and CH 2

CI

2 . The two portions were then mixed and stirred for half hour. The AgCl then formed was filtered off and the compound was recrystallized from hexanes. Yield: 15 mg, 73%. 25 WO 2009/055912 PCT/CA2008/001905 48 P H 2 A 'PhC H 2 PIA /N N AgCBijKBrs P 1 N /eGr N N Ru ) >CbI2Ru A~)CBIIjHG5rO A 1 \ hc C2 K2h-V N Ph / Ph Ph 31 P NMR 66.0 (d), 5.7 (d) Example 3: Alternate Route to Cationic Ruthenium Hydrogenation Catalysts In the syntheses described above, the neutral precursor complexes 5 were treated with anion abstracting agents to render the complexes cationic. The neutral precursors were generally derived from the ubiquitous ruthenium compounds [RuCI2(p-cymene)]2, [RuClz(benzene)]z or [RuCl 2 (cod)]n (cod = cyclooctadiene). These are common synthons used to prepare a range of ruthenium complexes and are known to be notoriously insoluble materials. As a result of the insolubility of these 10 complexes, the preparation of Ru derivatives from these material require long reaction times and forcing conditions. An alternate route to the same cationic ruthenium hydrogenation catalysts exists in the use of a cationic Ru precursor. Indeed, a cationic derivative of [RuCl2(p-cymene)] 2 holds the promise of improved solubility and thus shorter 15 reaction times and less forcing conditions. To this end, the reaction of [RuCl 2

(P

cymene)] 2 with anion abstracting agents was explored and found to yield the desired cationic synthon according to Scheme 2 below. The complexes [Ru 2 Cl3(p cymene) 2

][PF

6 ] and [Ru(MeCN) 3 (p-cymene)]2[BF4]2 were described by Bennett et al., J. C. S. Dalton Trans. 1974, 233. Limited synthetic and spectroscopic details were 20 provided in this report.

WO 2009/055912 PCT/CA2008/001905 49 Scheme 2 C 2>" ' 2 AgBF 4 F C ,, /. I IC 2[BF4] R6 Ru' -2AgC] 'Ru Rui LL L L F4] LL "C] PF4] 5 (a)[RuC(p-cymene)] 2 [BF4]2 In an Ar filled flask, 0.25 g (0.041 mmol) [RuCI 2 (p-cymene))2 and 0.16 g (0.082 mmol) of AgBF 4 were combined. CH 2 C1 2 (10 nL) was added and the 10 resulting orange suspension was left to stir at ambient temperature. Within several minutes the suspension darkened to brown/green in colour. After 2 hours, the suspension was filtered through Celite and the orange filtrate was reduced to approximately I mL in volume. Addition of hexane afforded an oily orange solid which was washed repeatedly with hexane and dried in vacuo. Yield: 0.215 g (74 %). 15 (b) In situ preparation of cationic ruthenium hydrogenation catalyst In an Ar filled flask, 0.070 g (0.11 mmol) [RuCI 2 (p-cymene)] 2 and 0,045 g (0.11 mrnol) of AgBF 4 were combined. CH 2 C1 2 (10 mL) was added and the resulting orange suspension was left to stir at ambient temperature. Within several minutes the suspension darkened to brown/green in colour. After 2 hours, the 20 suspension was filtered through Celite and the orange filtrate was collected and set to stir. A solution of R-BINAP (0.142 g, 0.11 mmol) in toluene (5 mL) was added. The resulting solution was stirred for several minutes. Solid R,R-cydn (0,026 g, 0. 11 mmol) was added, The resulting solution was heated to 60 *C for approximately 3 WO 2009/055912 PCT/CA2008/001905 50 hours. The resulting solution was concentrated to dryness leaving an orange residue. A sample of the residue was employed in the catalytic hydrogenation of acetophenone according to the conditions described below. Result: time = 2 h; conv. =>99%; ec 84%. 5 Example 4: Second Alternate Route to Cationic Ruthenium Hydrogenation Catalysts Yet another route exists via an ill-defined mixture of ruthenium diphosphine-DMF complexes (DMF = dimethylformamide) reported in the literature (Noyori et al., Tetrahedron Letters, 1991, 32, 4163). The mixture is believed to 10 consist of the following components: RuC1(diphosphine)(DMF) 2 and [RuCl2(diphosphine)(DMF)]n). Thus, treatment of the RuCi 2

(BINAP)(DMF)

2 and [RuCl 2 (BINAP)(DMF)]b) mixture with an equivalent of an anion abstracting agent (e.g. AgBF 4 ) to generate a cationic precursor which then react with a diamine (e.g. R,R-cydn) to yield the cationic ruthenium-diphosphine-diamine complex, [RuCI(R 15 BINAP)(R R-cydn)]BF 4 . This synthetic route is presented in Scheme 3 below. It should be noted that the product of this reaction also appears to be a mixture of the DMF-coordinated cation and the DMF-free cation. Scheme 3 RuCI 2 (BINAP)(DMF), 1. AgBF 4 , [RuCI(BINAP)(R, R-cydn)(DMF),]BF 4 20 2. R, R-cydn n=0, 1 This procedure can also be applied to the synthesis of compounds (I), (III) and (V) of this disclosure. 25 (a) [RuCl 2 (R-BINAP)DMF)n] In an Ar filled flask, 0.250 g (0.50 mmol) of [RuCl 2

(C

6

H

6

)]

2 and 0.622 g (1.00 mmol) of R-BINAP were combined. DMF (5 mL) was added and the resulting brown suspension was set to stir in a 100 "C oil bath. After 15 minutes, the suspension had cleared to a red/brown solution. The flask was removed from the oil 30 bath and allowed to cool to RT. The solution was then concentrated to an oily residue and Et 2 O (20 mL) was added affording brick red solids. The solids were filtered off in WO 2009/055912 PCT/CA2008/001905 51 air, washed with Et 2 O (5 x 5 mL) and dried in vacuo. Yield: 0.820 g (87 %). 31 P NMR (ppm, CD 2

C

2 ): several broad doublets between 50 - 62 ppm. (b) [RuCI(R-BINAP)(R, R-cydn)(DMF)]BF 4 In an Ar filled flask, 0.200 g (0,21 mmol) of RuCI2(R-BINAP)(DMF) 2 5 and 0.041 g (0.21 mmol) of AgBF 4 were combined. CH 2

C

2 (10 mL) was added and the resulting brown suspension was set to stir at ambient temperature. After 2 hours, 0.024 g (0.21 mmol) of RR-cydn in CH2Cl 2 (1 mL) was added and the suspension quickly changed to green in colour. The suspension was stirred for a further 2 hours and then filtered through a 0.45 mm PTFE syringe filter, The green filtrate was 10 concentrated to approximately 1 mL and Et 2 O (20 mL) was added affording green solids. The solids were filtered off in air, washed with Et 2 O (4 x 5 mL) and dried in vacuo. Yield: 0.186 g (85 %). " 3 P NMR (ppm, CD 2 C1 2 ): 7.38 (d, Jpp = 45 Hz), 67.4 (d, Jpp = 45 Hz). These chemical shift values match those for the same compound prepared via treatment of RuCI 2 (R-BINAP)(R, R-cydn) with one equivalent of AgBF 4 . 15 Minor peaks are also present between 48 - 54 ppm which are consistent with the presence of a small amount of a DMF adduct of the form "[RuCI(R-BINAP)(R,R cydn)(DMF)]BF 4 " which would account for the green colour (vs. orange for the same material prepared via treatment of RuCl 2 (R-BINAP)(RR-cydn) with AgBF4), (c) [RuCI(R-BINAP)(R,R-cydn)(DMF)]B(C 6 Fs)4 20 In an Ar filled flask, 0.200 g (0.21 mmol) of RuCI 2

(R-BINAP)(DMF)

2 and 0.185 g (0.21 mmol) of Li(OEt2)2,s[B(CF 5 )4} were combined. C1 2

C

2 (10 mL) was added and the resulting brown suspension was set to stir at ambient temperature. After 2 hours, 0.024 g (0.21 mmol) of R,R-cydn in CH 2

C

2 (I mL) was added and the suspension gradually changed to green in colour. The suspension was stirred for a 25 further 2 hours and then filtered through a 0.45 mm PTFE syringe filter. The green filtrate was concentrated to approximately 1 mL and hexane (20 mL) was added affording green solids. The solids were filtered off in air, washed with hexane (4 x 5 mL) and dried in vacuo. Yield: 0.333 g (96 %). 31 P NMR (ppm, CD 2 Cl 2 ): 7.31 (d, Jep = 45 Hz), 67.4 (d, Jpp = 45 Hz), These chemical shift values match those for the same 30 compound prepared via treatment of RuCl2(R-binap)(R,R-cydn) with one equivalent of Li(OEt 2

)

2

.[B(C

6

FS)

4 ]. Minor peaks are also present between 52 - 54 ppm which are consistent with a dmf adduct of the form "[RuC(R-BINAP)(RR- WO 2009/055912 PCT/CA2008/001905 52 cydn)(DMF)]B(C 6

F

5

)

4 " which would account for the green colour (vs. orange for the same material prepared via treatment of RuCI 2 (R-BINAP)(RR-cydn) with Li(OEt2)2.s[B(C 6 Fs) 4 ]). 5 Example 5: Third Alternate Route to Cationic Ruthenium Hydrogenation Catalysts Another route to a cationic ruthenium catalyst exists through the stable precursor RuCl2(diphosphine)(pyridine) 2 . It has been determined that RuCI2(diphosphine)(pyridine) 2 is a highly useful and convenient precursor to complexes of the type (RuC(diphosphine)(diamine)LB]X and [RuCl(diphosphine) 10 (aminophosphine)LB]X, The precursor, RuCl 2 (diphosphine)(pyridine) 2 is a well defined, single component (in contrast to the DMF analogue of Example 4). RuCl 2 (diphosphine)(pyridine)2 can be prepared from the corresponding DMF complex or in an analogous method to the preparation for the DMF complex wherein pyridine is used instead of DMF, as shown in Scheme 4. 15 Scheme 4 Route 1: P Ph N PhPhcl ' Ru- (DMF)n Ru 31PNNW: 40.1 (s) Ph Ph Phh Route 2: N Ph Ph 1/2[RuCI 2 (p-cymene)] 2 + binap Ru 31P NNR: 40.1 (s) toluene y \1 C ph PhC ,r 20 The precursor compound RuCl 2 (diphosphine)(pyridine) 2 is readily derivatized into its cationic counterpart, (RuCI(diphopshine)(pyridine) 2

]BF

4 , by treatment with an anion abstracting agent (e.g. AgBF 4 as set out in Scheme 5), WO 2009/055912 PCT/CA2008/001905 53 Scheme 5 PhPhC, PhPh /') P /Ns AgBF 4 P- Ns G KWRuN,NP R\ BF4 Pxh Ph PhPh'0 31P NMR: 53.2 (s) The cation, an air stable solid which can be isolated in high yields and 5 stored under ambient conditions, is a convenient precursor to other cationic hydrogenation catalysts. The cationic pyridine compound can be derivatized by treatment with a diamine into compounds of the type [RuCl(diphosphine)(diarnine)]BF 4 (Examples 5(a) and (b)). An alternate route to complexes of the type 10 [RuCI(diphosphine)(pyridine) 2 ]+ via a ruthenium-norbornadiene (NBD) complex which is equally valuable is outlined below in Scheme 6. It should be noted that pyridine can be replaced by any Lewis base and the product can be further derivatized to complexes of the type {RuCl(diphosphine)(diamine)LB]X and (RuCI(diphosphine)(aminophosphine)LB]X (where LB is Lewis base). i5 Scheme 6 2RuC13aH 2 O + 2 * CHCH2O 2 HCI + C ] AgBF cR J 1 week The procedures described in this Example can be generalized into the 20 following method for the preparation of cationic or dicationic catalysts: WO 2009/055912 PCT/CA2008/001905 -54 Scheme 7

[MX

2 (ligand)]b anion abstracting I agent [MX(diphosphine)(LB) 2 + diphosphine b, MX 2 (diphosphine)(LB) 2 - or fM(diphosphine)(LB) 2 2+ " Lewis base (LB 5 wherein M, X and LB are as defined for the compounds of the disclosure and diphosphine is a P2 ligand as defined for the compounds of the disclosure and ligand is a neutral displaceable ligand such as p-cymene, benzene, COD and NBD and x is an integer that depends on the structure of the complex (typically x is 2). The cationic catalysts derived from the precursors described in this 10 Example have been tested in hydrogenation using identical procedures as for the cations derived from treatment of the RuCl 2 (diphosphine)(diamine) or RuCl 2 (diphosphine)(PN) complexes with anion abstracting agents in the presence of Lewis bases. The complexes prepared via the [RuCI(PP)(py) 2 jBF 4 precursor display essentially identical behavior in hydrogenation of acetophenone. 15 (a) [RuCl(R-binap)(R,R-cydn)(py)]BF 4 To a CH 2

CI

2 solution of [RuCl(R-binap)(py) 2

]BF

4 (0.08 g, 0.0796 mmol) was added a CH 2 C1 2 solution of the R-R-cydn (9.1 mg, 0.0796 mmol) under inert (Ar) atmosphere. The reaction mixture was allowed to stir overnight at ambient temperature. The solution was then concentrated, and the residue was recrystallized 20 from CH 2

CI

2 /Et 2 0. The solid that precipitated was then filtered in air to obtain an amber-yellow color solid. Yield: 0,06 g, 70%, This catalyst was examined for its catalytic ability to convert acetophenone to its corresponding alcohol, and showed a 98% conversion with an enantiomeric excess of 80%.

WO 2009/055912 PCT/CA200S/00190 5 55 Phph H2N CIH N NNHP N Ru BF 4 Ru BF 4 P' \ N p \ 11NO P PhCi t Ph H2 0 31P NMR: 60.0 (d) Hydrogenaton: 98% conversion (acetophenone) 80 % ee (b) [RuCI(R-binap)(Ph 2

PCH

2 C H2NH2)(py)]BF4 To a CH 2

C

2 solution of the [RuCl(R-binap)(py)2]BF 4 (0.077 g, 0,0770 mmol) was added a CH 2

CI

2 solution of 2-(diphenylphosphino)ethylamine (17.6 mg, 5 0.0770 mmol) under inert atmosphere. The reaction mixture was allowed to stir overnight at ambient temperature. During this time some precipitate formed. The solution was then filtered, the filtrate was concentrated, and the residue was recrystallized from CH 2 Cl 2 /Et 2 O. The solid that precipitated was then filtered in air to obtain an amber-yellow color solid. Yield: 0.05 g, 54%. This catalyst was examined 10 for its catalytic ability to convert acetophenone to its corresponding alcohol, and showed a 72% conversion and an enantiomeric excess of 22%. Ph Ph 2 P-'-NH2 Ph PhPha PN NNs e PP IPN P Ru BF 4 Ru BF 4 I\ N' N P Ph PhPh\ H2 31P NMR: 53.4 (s) Hydrogenaion: 72% conversion (acetophenone) 22 % ee (c) [RuCI(NBD)(py)2]BF 4 (As per Scheme 6 above) 15 The first step of the reaction is carried out in air. To a 500 mL schlenk flask containing a pear-shaped stirring bar is charged with a ethanol solution (200 mL) of RuCb,3H 2 0, and bicycle [2.2.1] hepta-2,5-diene (norbornadiene) (10 mL, WO 2009/055912 PCT/CA2008/001905 56 0.12 mol). The mixture is vigorously stirred at room temperature for 24 hour. During this time the brick red to brown solid precipitated from the solution. On completion of the reaction the suspension is filtered using a medium porosity glass filter frit and washed thoroughly with acetone (50 mL). Drying of the solid gives 3.8 g of insoluble 5 brick red solid. (ref Inorganic Syntheses. New York: John Wiley and Sons, 1989: 250 -251) The second step of the reaction is carried out under Argon and the work-up procedure was slightly modified from the original literature. [(NBD)RuCl2]x (2.0 g, 7.57 mmol) was rapidly stirred in pyridine (50 mL) for 1 week at room 10 temperature under argon. The mixture changed from brown to greenish-yellow over this period. The pyridine was then removed under vacuum to give a greenish yellow solid. The solid was then dissolved in CH 2 Cl 2 and the insoluble black material was filtered off. The CH 2 Cl 2 solution was then concentrated, and recrystallized from hexanes 2 times, yielding a dark-orange crystalline materials. Yield: 3.0 (93%). 'H 15 NMR (400 MHz, CD 2 Cl 2 ): d 1.55 (br s, 2H, CH 2 ), 4.05 ( br s, 2H, bridgehead CH), 4.85 (m, 4H, olefin), 7.25 (br t, J= 11.9 Hz, 4H), 7.7 (br t, J= 11.9 Hz, 2H), 8.54 ( br d, J = 12.0 Hz, 4H).(ref Chirality 2000, 12: 514 - 522) The third step of the reaction is carried out in the dry box. To a small vial is charged (NBD)RuC 2 (Pyridine)2 (0.1 g, 0.23 mmol) and I equiv. of AgBF 4 (46 20 mg, 0.23 mmol) and CH 2 C1 2 (5 mL). The solution was allowed to stir for 1 hour. Precipitate was observed during this period. The precipitate was then filtered off, and the filtrate was concentrated and recrystallized from Et 2 O to obtain a pale greenish yellow solid. Yield: 80 mg, 72%. 25 Example 6: Synthesis of Dicationic Ruthenium Hydrogenation Catalysts (a) [Ru(R-binap)(R, R-cydn)][BF4] 2 In an Ar filled flask, 0.100 g (0.11 mmol) of RuCl 2 (R-binap)(R,R cydn) and 0.045 g (0.24 mmol) of AgBF 4 were combined, CH 2

CI

2 (7 mL) was added and the resulting rust coloured suspension was left to stir at ambient temperature for 30 two hours after which time it was filtered through Celite. The orange filtrate was reduced to dryness leaving a yellow/orange residue. Yield: 0.085 g (77 %). 31 P NMR (ppm, CD 2 Cl 2 ): 0.48 (d, Jp = 39 Hz), 64,89 (d, Jpp = 39 Hz).

WO 2009/055912 PCT/CA2008/001905 57 H22+ Ph2_ N R [BF412 (b) [Ru (R-binap)(Ph 2

PCH

2

CH

2

NH

2 )][BF4]2. 5 In an Ar filled flask, 0,115 g (0.11 mmol) of RuCl2(R binap)(Ph 2

PCH

2

CH

2

NH

2 ) and 0.044 g (0.24 mmol) of AgBF 4 were combined.

CH

2 C1 2 (7 mL) was added and the resulting dark orange suspension was left to stir at ambient temperature for two hours after which time it was filtered through Celite. The yellow filtrate was concentrated to approximately I mL in volume and Et 2 0 was 10 added (10 mL) affording pale yellow solids. The solids were filtered off, washed with Et 2 0 (3 x 5 mL) and dried in vacuo. Yield: 0.119 g (94 %). 3 P NMR (ppm, CD 2 Cl 2 ): 15.3 (d, Jpp = 18 Hz), 17.2 (d, Jpp = 18 Hz), 62.2 (br m). 12+ P' p [BF 4

]

2 Ph2 Ph2 15 (c) [Ru(R,R-DPPcydn)][BF4]2 In an Ar filled flask, 0.200 g (0.20 mmol) of RuCI 2 (R,R-DPPcydn) and 0.093 g (0.48 mmol) of AgBF 4 were combined. CH 2 C1 2 (7 mL) was added and the resulting dark yellow/green suspension was left to stir at ambient temperature for two 20 hours after which time it was filtered through Celite. The yellow filtrate was concentrated to approximately I mL in volume and Et 2 0 was added (10 mL) affording pale yellow solids, The solids were filtered off, washed with Et 2 0 (3 x 5 mL) and dried in vacuo. Yield: 0.169 g (92 %). 3 1P NMR (ppm, CD 2 Cl2): broad signals at 42.2 and 63.3 ppm barely discernable above baseline, 25 WO 2009/055912 PCT/CA2008/001905 58 2+ [SF412 NH NH [F] CP R Ph 2 Ph, Example 7: Lewis Base Adducts of Dicationic Catalysts (a) .7 .7 .7 ~ NCC1Hs CHCN N2NBFK Ru/l Ru 2 Be Ph 2 Hz 2 5 2 BF 6 NCCH, "P NMR 49.8 (d), 42.9 (s), 42.1 (d). (b) NN Phh 1 N 7I p~ NN K 2BF Ph 2 H, N P "P NMR: 61.4 (d), 59.2 (d), 51.9 (s), 46.6 (d), 44.8 (d). 10 (c) N N" R/ ON Ru \2 BF? N 7 4 2 BF?7 0 "P NMR: 62.2 (br), 42.2 (br).

WO 2009/055912 PCT/CA2008/001905 59 (d) 0 cots) 2h BF \,h P NMR 313 s, 1 s, 9 (d, 46Id I IB/ R \, P2 BF 4 A4 NV\ K p N : 5 8 2 BF? C P NMR: 31.3 (s), 31.1 (s), 2 9.8 (d), 24.6 (d), Ph, 142 .2 .IBtuCN A N /Uiu,J,..> 7 Ph 2 Ph2 5~~ BFFE N A 28 NF A CIBuO "P NMR: 50.4 (d), 42.3 (s), 41.4 (d). C)N Ru \N Ru\ 2SBF? Ph: Ph2 2 BF? NB 10 "P NMR: 42.4 (d), 42.4 (s), 33.0 (d).

WO 20091055912 PCT/CA20098/001905 60 Example 8: Cationic Iron Hydrogenation Catalysts (a) Bis(acetonitrile) N',N 2 -bis(2-(diphenylphosphino)benzylidene)(R,R)-cyclohexane 1,2-diamine iron (I)tetrafluoroborate, [Fe(N'CMe)2((R,R)-cyPPh 2 N2)][BF4], 5 Me C 'IF [BF 4

]

2 Fe 10 Ph 2 N Ph 2 III C Me 15 Acetonitrile (5 mL) was added to 210 mg (0.319 mmol) of N',N 2 bis(2-(diphenylpbosphino)benzylidene)cyclohexane-1,2-diamine, (R,R)-cyP2N2 and 102 mg (0.302 mmol) of iron (II) tetrafluoroborate hexahydrate [Fe(OH 2

)

6

][BF

4

]

2 and the mixture was stirred for one hour. The solution was concentrated to ca. I mL and then 20 mL of diethyl ether was added dropwise. The mixture was stirred for 30 20 minutes and then the solid was collected on a glass frit and dried in vacuo. Yield: 240 mg, 82 %. "P{'H} NMR (121 MHz, CD 3 CN): 52.7 ppm.

WO 2009/055912 PCT/CA2008/001905 61 (b) Bis(acetontrile) N',N<bis(2-(diolylphosphino)benzyl)(R,R)-cyclohexane-1,2 diamine iron(I)tetrafluoroborate, [Fe(NCMe)2((R, R)-cyPAr 2 (NH)2)][BF4]2 Me C 5

[BF

4

]

2 H>H FeZ N Ar 2 N Ar 2 if]i C 10 Me Ar =4-MeC 6

H

4 A solution of N',N 2 -bis(2-(ditolylphosphino)benzyl)(R,R) cyclohexane-1,2-diamine (R,R)-cyPAr 2

(NH)

2 (149 mg, 0.207 mmol) and iron (II) 15 tetrafluoroborate hexahydrate [Fe(OH 2

)

6

][BF

4 Jz (70 mg, 0.207 mmol) was stirred at r.t. in MeCN (5 mL) for 20 min. The resulting purple solution was concentrated to I mL and 10 mL of Et 2 O were added. A purple powder precipitated and was isolated by filtration. Yield: 170 mg, 87%. "P{'H} NMR(121 MHz, CD 3 CN): 35.3 ppm.

WO 2009/055912 PCT/CA2008/001905 62 (c) Bis(acetonitrile) N' N 2 -bis(2-(dixylylphosphino)benzyl)(R, R)-cyclohexane-1,2 diamine iron(II)tetrafluoroborate, [Fe(NCMe)2((R, R)-cyPAr2(NH)7)][BF4]2 5me C :Z [BF4]2 10 Fe N Ar2 N Ar2 IiI C Me Ar 3,5-Me 2

C

6

H

3 15 A solution of N',N 2 -bis(2-(dixylylphosphino)benzyl)(R,R) cyclohexane-1,2-diamine (R,R)-cyPAr2(NH)2 (161 mg, 0.207 mmol) and iron (II). tetrafluoroborate hexahydrate [Fe(OH 2

)

6

][BF

4

]

2 (70 mg, 0.207 mmol) was stirred at r.t. in MeCN (5 mL) for 20 min. The resulting purple solution was concentrated to 1 20 mL and 10 nL of Et 2 O were added. A purple powder precipitated and was isolated by filtration. 3: Yield: 190 mg, 91%. "P('H} NMR (121 MHz, CD 3 CN): 39.2 ppm.

WO 2009/055912 PCT/CA2008/001905 63 (d) Bis(acetonitrile) N, N 2 -bis(2-(3, 5-di-tert-butyl-4-methoxy phenylphosphino)benzyl) (R, R)-cyclohexane-1, 2-diamine iron(II)tetrafluoroborate, [Fe(NCMe) 2 ((R, R)-cyPAr 2

(NH)

2

)][BF

4

]

2 Me 5 C

[BF

4

]

2 P Fe N 10 6 Ar 2 N Ar 2 I L C Me Ar = 3,5-Me 2 -4-OMe-C 6

H

2 A solution of N ,N 2 -bis(2-(3,5-di-tert-butyl-4-methoxy 15 phenylphosphino)benzyl)(R,R)-cyclohexane-1,2-diamine (R,R)-cyPAr 2

(NH)

2 (255 mg, 0.207 mmol) and iron (11) tetrafluoroborate hexahydrate [Fe(OH2)6][BF 4 ]2 (70 mg, 0.207 mmol) was stirred at r.t. in McCN (5 mL) for 20 min. The resulting brown solution was concentrated to 1 mL and 10 mL of Et 2 O were added. A beige-brown powder precipitated and was isolated by filtration. Yield: 190 mg, 91%. 20 " 3 P{'H} NMR (121 MHz, CD3CN): 47.5 ppm, WO 2009/055912 PCT/CA2008/001905 64 (e) Bis(acetonitrile) N N 2 -b is(2-(diphenylphosphino)benzylidene) (R, R) diphenylethylene-1, 2-diamine iron(II)tetrafluoroborate, [Fe (NCMe)2((R,R) dpenPPhN 2

)][BF

4

]

2 5 Me C Ph N Ph [BF4]2 N 10 pN F P Ph 2 N Ph 2 Iri C Me 15 Synthesis of [Fe(NCMe) 2 ((R,R)-dpenPPh 2

N

2

)][BF

4 ]2, (5). A solution of (lR,2R)-(+)-1,2-diphenylethylenediamine (63 mg, 0.297 mmol), 2 (diphenylphosphino)benzaldehyde (172 mg, 0.593 mmol), and iron (II) tetrafluoroborate hexahydrate [Fe(OH 2

)

6

][BF

4 2 (100 mg, 0.296 mmol) was stirred 20 overnight under reflux in MeCN (5 mL). The red orange solution was concentrated to I mL and 10 mL of Et 2 0 were added. A red-orange powder precipitated and was isolated by filtration. Yield: 290 mg, 92%. "P{'H} NMR (121 MHz, CD 3 CN): 52.3 ppm, WO 2009/055912 PCT/CA2008/001905 65 () [Fe(CN'Bu) (NCMe)((R, R)-dpenPPh 2

N

2

)][BF

4

]

2 Me C 5 Ph N Ph [BF4] 2 JN Fe Ph 2 C Ph 2 I Fm N 10 tBu A solution of [Fe(NCMe)2((R,R)-dpen-PPh2N2)][BF 4 ]2 (130 mg, 0.122 mmol) and tBuNC (14 pL, 0.122 mmol) in acetone (3 mL) was stirred for 15 min. The resulting orange-yellow solution was evaporated to dryness to give an orange 15 powder). 6: Yield: 55 mg, 41%. 31 P{'H} NMR (121 MHz, CD3CN): 56.1 ( 2 Jp 48 Hz), 44.8 ( 2 Jp.p= 48 Hz) ppm. (g) [Fe(CN'Bu)(NCMe)((R, R)-cyPPh 2 N)][BA rF 20 Me C [BArF 2 25 Fe Ph 2 C Ph 2 III N Bu 30 A solution of [Fe(NCMe)2((R,R)-cy-PPh 2

N

2

)][BF

4 ]2 (40 mg, 0.039 mmol) and NaBArF (71 mg, 0.079 mmol) in dichloromethane (5 mL) was stirred for 1 hour. The resulting orange-yellow solution was filtered on celite and evaporated to WO 2009/055912 PCT/CA2008/001905 66 dryness to give an orange powder. 7: Yield: 90 mg, 89%. P{'H} NMR (121 MHz,

CD

3 CN): 55.2 ( 2 Jpp= 54 Hz), 48.1 ( 2 .Jpp= 54 Hz) ppm. (h) [Fe(CO)(NCMe)((R, R)-dpenPPhN 2 )][BF4] 2 Me 5 C ill Ph -N Ph [BF4]; N Fe PN 10 Ph 2 C Ph 2 Ill L ~0 A solution of Fe(NCMe)2((R,R)-dpenPPPh 2

N

2 )][BF4] 2 (185 mg, 0.173 15 mmol) in acetone (10 mL) was stirred under CO overnight. The resulting orange solution was evaporated to dryness to give an orange powder, The NMR of the crude product shows an AB pattern characteristic of the formation of [Fe(CO)(NCMe)((R,R)-dpenPh2N2)][BF 4

]

2 , (7) (purity < 50%) with other unidentified impurities. "P{'lH} NMR (121 MHz, CD 3 CN): 52.9 ( 2 Jp.p = 40 Hz), 49.7 ( 2 J.p = 40 20 Hz), 9.1, -2.4, -19.6, -22.1 ppm. Example 9: General Procedure for Hydrogenation with Ruthenium Complexes A solution of acetophenone (1.0 g, 8.3mmol) in 2-propanol (1Oml) was added to a 50 mL Schlenk flask. After evacuating and refilling with argon, a mixture 25 of catalyst (e.g. [RuCI(R-binap)(R,R-cydn)]BF 4 ; 0.01mmol) and K'OBu (20 mg, 0.18mrnol) was added. The resulting mixture was then injected into a 100 mL autoclave which had been previously placed under an atmosphere of H 2 . The autoclave was pressurized to 200 psig and the reaction mixture was stirred at ambient temperature. The reaction progress was monitored by TLC. Upon completion of the 30 reaction, the solvent was removed under vacuum and the mixture was filtered through silica gel (ca. 6 cm) using 3:1 hexane:ethyl acetate. The solvent was removed from WO 2009/055912 PCT/CA20081001905 67 the filtrate affording the product as a colorless liquid. Results are shown in Tables I 9. 5 Example 10: Hydrogenation of2,3,3-trimethylindolenine catalyst N H 2 /KOtBu/'PrOH N H A solution of 2,3,3-trimethylindolenine (0.286 g, 1,8 mmol) in 2 10 propanol (10 mL) was added to a 50 mL Schlenk flask. After evacuating and refilling with argon, a mixture of catalyst (0.01 mmol) and KOtBu (29 mg, 0.26 mmol) was added. The resulting mixture was then injected into a 100 mL autoclave which had been previously placed under an atmosphere of H 2 . The autoclave was pressurized to 150 psi and the reaction mixture was stirred at ambient temperature. A solution of 15 Na 2

CO

3 was added to render the mixture basic. The product was extracted with

CH

2

CI

2 . The resulting organic phases were dried on MgSO 4 , filtered and evaporated to dryness. The 'H NMR analysis was used to calculate the conversion. The sample was purified by chromatography on silica gel using hexane and ethyl acetate and submitted for HPLC analysis to determine the e.e. The results are presented in Table 20 10. Example 11: Hydrogenation of Norcamphor o KOtBu/PEOH Z - _OH +

H

2 , catalyst exo endo 25 A solution of norcamphor (0.64 g, 5.82 mmol) in 2-propanol (5 mE) was added to a 50 mL Schienk flask. After evacuating and refilling with argon, a WO 2009/055912 PCT/CA2008/001905 68 mixture of catalyst (i.e. [RuC(Ph 2

PCH

2

CH

2

NH

2

)

2

]BF

4 ; 0.010 g, 0.015 mmol) and K'OBu (0.02 g, 0.18 mmol) in 2-propanol (5 mL) was added. The resulting mixture was then injected into a 100 mL autoclave which had been previously placed under an atmosphere of H2. The autoclave was pressurized to 200 psig and the reaction mixture 5 was stirred at ambient temperature. The reaction progress was monitored in NMR. Results for [RuCl(Ph 2

PCH

2

CH

2

NH

2

)

2

]BF

4 : 99:1 endo:exo. Example 12: Hydrogenation of acetophenone using cationic iron complexes (a) H 2 conditions 10 Under argon, a solution of degassed acetophenone (120 mg, 1 mmol) and KO'Bu (4.5 mg, 0.04 mmol) was added to a Schlenk flask. The resulting mixture was then injected into a 100 mL autoclave which already contains the iron catalyst (5 mg, 0.005 mmol) and 6 mL of degassed 2-propanol. under an atmosphere of H 2 . The autoclave was pressurized to 25 atm and the reaction mixture was stirred at 50 *C. 15 After 17 hours, the sample was then filtered through silica gel (ca, 2 cm) using

CH

2 C1 2 and submitted for GC analysis. The results are shown in Table 11 (b) Transfer hydrogenation conditions Under argon, the iron complex (5 mg, 0.005 mmol), KOtBu (5 mg, 0.045 mmol) and acetophenone (120 mg, 200 equiv) were stirred in 5 mL of 2-propanol at r.t, The 20 sample was then filtered through silica gel (ca. 2 cm) using CH2Ci 2 and submitted for GC analysis. The results are shown in Table 12, While the present disclosure has been described with reference to what are presently considered to be the preferred examples, it is to be understood that the disclosure is not limited to the disclosed examples. To the contrary, the disclosure is 25 intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims. All publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to 30 be incorporated by reference in its entirety. Where a term in the present application is found to be defined differently in a document incorporated herein by reference, the definition provided herein is to serve as the definition for the term.

WO 2009/055912 PCT/CA2008/001905 69 TABLE . RESULTS OF THE HYDROGENATION OF ACETOPHENONE CATALYSED BY CATIONIC COMPLEXES OF RUTHENIUM 0 OH

H

2 /Cat/K t OBu 2-propanol, RT 5 Entry Complex Time(h) Conv.(%) ee (%) I [RuCl(R-binap)(RR-cydn)jBF 4 1 >99 80 2 [RuCI(R-binap)(RR-cydn)CH 3

CN]BF

4 17 >99 84 3 [RuCl(R-binap)(RR-cydn)py] BF 4 17 >99 83 4 [RuCl(R-binap)(R,R-cydn)][B(C 6

F)

4 ] 17 >99 82 5 [RuCI(R-binap)(Ph 2 PCIICH2NH2)]BF 4 2 >99 84 6 [RuCl(R-binap)(Ph 2

PCH

2

CH

2

NH

2

)]B(C

6

F

5

)

4 2 >99 83 7 [RuCI(S-binap)(S,S-Ph2PCH(Ph)CH(Ph) 17 >99 26

NH

2

)]BF

4 8 [RuCI(R-binap)(S,S-Ph2PCH(Ph)CH(Ph) 3 >99 69

NH

2

)]BF

4 9 [RuCl(Ph 2

PCH

2 CH2NH2)2]BF 4 1 >99 n/a 10 [RuCl(Ph 2 PCH2CH2NH2) 2 ][B(CFs) 4 ] 0.5 >99 n/a 11 [RuCl(R-tolbinap)(R,R - 7 70 52 Ph 2 PCH(Ph)CH(CH 3

)NH

2

]BF

4

--

12 [RuCl(R-tolBinap)(R,R - 8 >99 51 Ph 2 PCH(Ph)CH(CH 3

)NH

2

)[B(C

6 Fs) 4 ) 13 [RuCI(R-3,5-xylylbinap)(R,R - 17 70 20 Ph 2 PCH(Ph)CH(CH 3

)NH

2

]BF

4 14 [RuCI(R-3,5-xylylbinap)(R,R - 7 60 33 Ph 2 PCH(Ph)CH(CH 3 )NH2][B(C 6 FS)4] 15 [RuCI(PPhs) 2 (NH2CH2-Py)]BF 4 3 >99 n/a 16 [RuC(PPh 3 )2(NH2CH2-Py)][B(C 6

F)

4 ] 3 >99 n/a 17 [RuCI(R-Binap)(Sc,Rp-NH 2

-CH(CH

3 )-Fe- 22 41 15 PPh 2

)]BF

4 18 [RuCI(R-Binap)(Rc,Sp-NH 2

-CH(CH

3 )-Fc- 22 85 0.5 PPh 2 )1BF 4 WO 2009/055912 PCT/CA2008/0019 0 5 70 19 [RuC(R-Binap)(Sc,Rp-NH 2

-CH(CH

3 )-Fc- 22 38 6.4 PPh2)]B(C 6

FS)

4 20 [RuC(R-Binap)(Rc,Sp-NH-CH(CH 3 )-Fc- 22 63 14 PPh2) [B(C 6

F

5

)

4 1 21 [RuCI(1R,2R-(Ph2PCH 4

CH

2

NH)

2

C

6 HIo)]BF 4 1.5 >99 24.3 22 [RUC(IR,2R-(Ph2PC 6

H

4 CH2NH) 2

C

6 Ho)) 1.5 >99 6.7

[B(C

6

F

5 )4] 23 [RuCI(1R,2R-(4-methyl- 1.5 >99 23.5 Ph 2

PCH

4

CH

2

NH)

2

C

6 Ho)]BF 4 24 [RuC(IR,2R-(4-methyl- 1.5 >99 6.4 Ph2PC 6

H

4

CH

2

NH)

2

C

6 HIo)][B(C 6 F5) 4 ] 25 [RuCI(1R,2R-(3,5-dimethyl- 1.5 >99 73 Ph 2

PC

6

H

4

CH

2

NH)

2

C

6 Hio)]BF 4 26 [RuC1(I R,2R-(3,5-dimethyl- 1.5 >99 74,5 Ph 2

PCH

4

CH

2

NH)

2 CHIo)[B(C 6

F

5 )4] 27 RuCI 2 (S-PPhos)(S-DAIPEN) 5 >99 71 (Comparative Example) 28 [RuC(S-PPhos)(S-DAIPEN)]BF 4 4 >99 89.3 29 [RuC](S-PPhos)(S-DAIPEN)]B(C 6 Fs) 4 4 >99 88.7 30 RuCl2(S-xylylPPhos)(S-DAIPEN) 3 >99 97.3 (Comparative Example) 31 [RuCl(S-xylylPPhos)(S-DAIPEN)IBF 4 4 >99 99.3 32 [RuCI(S-xylylPPhos)(S-DAIPEN)]B(CsF) 4 4 >99 98.7 33 RuC1 2 (S-BINAP)(S-DAIPEN) 3 >99 87 (Comparative Example) 34 [RuCI(S-BINAP)(S-DAIPEN)BF 4 4 >99 85 35 [RuC(S-BINAP)(S-DAIPEN)]B(C 6

F

5

)

4 4 >99 87 36 [RuCl 2 (S-PhanePhos)(R,R-DPEN)] 3 >99 95.6 (Comparative Example) 37 [RuCI(S-PhanePhos)(R,R-DPEN)]BF 4 3 >99 97,5 38 [RuCI(S-PhanePhos)(R,R-DPEN)]B(C 6

F

5

)

4 3 >99 98 39 {RuCl2(S-Xyly]PhanePhos)(RR-DPEN)] 3 >99 96,8 (Comparative Example) 40 [RuC](S-XylylPhanePhos)(RR-DPEN)]BF 4 3 >99 96,6 41 [RuCI(S-XylylPhanePhos)(R,R- 3 >99 97.8

DPEN)]B(C

6 F5) 4 42* fRuCl(PPh 3

)

2 ((S)-1-(pyridin-2- 1.5 65 15.5 WO 2009/055912 PCT/CA2008/001905 71 ylethanamine)]BF4 5 >99 15.5 43* (RuCI(S-XylylPPhos)((S)-1-(pyridin-2- 3 >99 53 yl)ethanamine)]BF 4 44* [RuCI(R-BINAP)((S)-I-(pyridin-2- 3 >99 3 yl)ethanamine)]BF 4 45* [RuCI(Sc,Rp-PCy 2

-CH(CH

3 )-Fc-PCy 2 )((S)-1- 1.5 >99 23.7 (pyridin-2-yl)ethanamine)]BF 4 46 [RuC(R-binap)(RR-cydn)(dmf).]BF 4 4 100 82 47 [RuCl(R-binap)(R,R-ydn)(dmf)jB(C 6 Fs) 4 4 100 80 Substrate:Ru = 830, PH 2 =160Psi. *Substrate:Ru:Base = 1000:1:12, PH 2 = 170 psi 5 WO 2009/055912 PCT/CA2008/001905 72 TABLE 2. RESULTS OF THE HYDROGENATION OF ACETOPHENONE CATALYSED BY CATIONIC COMPLEXES OF RUTHENIUM COMPARING DIFFERENT COUNTER ANIONS. Entry Cat Time (h) Conv. ee (%) (%) 1 (R-binap)RuCl2(R,R-dach) 17 >99 83 2 [(R-binap)RuC1(R,R-dacb)]BF 4 1 >99 80 3 [(R-binap)RuC(RR-dach)]PF 6 17 >99 78 4 [(R-binap)RuCl(RR-dach)]OTf 17 >99 78 5 [(R-binap)RuC1(RR-dach)]B(CFs) 4 17 >99 82 6 [(R-binap)RuCl(R,R-dach)][B(3,5-(CF3) 2 C6H3)4] 17 >99 82 7 (R-binap)RuCl2(PGly) 17 >99 23 8 [(R-binap)RuCl(PGly)]BF 4 2 >99 84 9 [(R-binap)RuCI(PGly)]PF 6 17 99 73 10 [(R-binap)RuC(PGly)]OTf 17 >99 30 11 [(R-binap)RuCl(PGly)}B(CF 5

)

4 2 >99 83 12 [(R-binap)RuCl(PGly)][B(3,5-(CF 3

)

2 C6H3)4]. 17 >99 43 13 RuCl2(PGIy) 2 17 >99 14 [RuC1(PGly) 2

]BF

4 1 99 15 [RuCl(PGIy) 2

]PF

6 17 >99 16 (RuC(PGly)2}OTf 17 >99 17 [RuCJ(PGly)2]B(C6Fj) 4 0.5 >99 18 [RuC1(PGly)2}{B(3,5-(CF 3 )2C6H3)4]. 17 >99 19 [(R-binap)RuC1(RR-dach)(MeCN)]BF4 17 >99 84 20 [(R-binap)RuCl(R, R-dach)(pyr)]BF 4 17 >99 83 5a S:C:B = 830:1:18, iPrOH, r.t., PH2= 150 psi WO 2009/055912 PCT/CA2008/001905 73 TABLE 3, RESULTS OF THE HYDROGENATION OF 4-FLUORO ACETOPHENONE CATALYSED BY CATIONIC COMPLEXES OF RUTHENIUM. OH N. Cat/KtOBu N Fj / 2-propanol, RT Entry Complex Time(h) Conv.(%) ee (%) 1 [RuCl(S-PPhos)(S-DAIPEN)]BF 4 4 >99 73.6 2 [RuC(S-PPhos)(S-DAIPEN)]B(C 6

F

5

)

4 4 >99 77 3 [RuCI(S-xylylPPhos)(S-DAIPEN)]BF 4 4 >99 99.1 4 [RuCI(S-xylylPPhos)(S- 4 >99 99

DAIPEN)]B(C

6

F

5

)

4 5 [RuCl(S-BINAP)(S-DAIPEN)]BF 4 4 >99 75.4 6 [RuCI(S-BINAP)(S-DAIPEN)]B(C 6

F

5

)

4 4 >99 78.8 Substrate:Ru = 830, PH2=160Psi 10 WO 2009/055912 PCT/CA2008/001905 74 TABLE 4. RESULTS OF THE HYDROGENATION OF 3,5 BIS(TRIFLUOROMETHYL)-ACETOPHENONE CATALYSED BY CATIONIC COMPLEXES OF RUTHENIUM. 0 on

F

3 C Cat/KtOBu a F3C 2-propanol, RT 5 3 CF 3 Entry Complex Time(h) Conv.(%) ee (%) I [RuCl(S-PPhos)(S-DAIPEN)]BF 4 2 >99 74 2 [RuC(S-PPhos)(S-DAIPEN))B(C 6

F

5

)

4 2 >99 75.5 3 [RuCI(S-xylylPPhos)(S-DAIPEN)]BF 4 2 >99 99.0 4 [RuCl(S-xylylPPbos)(S- 2 >99 99.0

DAIPEN)]B(C

6

F

5

)

4 5 [RuCI(S-BINAP)(S-DAIPEN)]BF 4 2 >99 77 6 {RuCl(S-BINAP)(S-DAIPEN)]B(C6F) 4 2 >99 78.7 10 WO 2009/055912 PCT/CA2008/001905 75 TABLE 5. RESULTS OF THE HYDROGENATION OF 3-TRIFLUOROMETHYL ACETOPHENONE CATALYSED BY CATIONIC COMPLEXES OF RUTHENIUM. 0 OH 11 2 /Cat/K'OBu 2-propanol, RT 5 CF 3

CF

3 entry Cat. Time(h) Conv.(%) ee (%) I [RuCl(S-PPhos,S-DAIPEN)]BF 4 1 >99 76 2 [RuCI(S-PPhos,S-DAIPEN)]B(C 6

FS)

4 1 >99 81 3 [RuCI(S-xylylPPhos,S-DAIPEN)]BF 4 1 >99 98.7 4 [RuCl(S-xylylPPhos,S-DAIPEN)]B(C 6

F)

4 1 >99 98.5 5 {RuC(S-BINAP,S-DAIPEN)]BF 4 1 >99 76.5 6 {RuCl(S-BINAP,S-DAIPEN)]B(C 6

F)

4 1 >99 76.7 7 [RuCl 2 (S)-PhanePhos,(R,R)DPEN) 17 >99 65.3 8 [RuC(S)-PhanePhos,(R,R)DPEN]BF 4 17 >99 78.5 9 [RuCl(S)PhanePhos,(R,R)DPEN]B(C 6

F

5

)

4 17 >99 81.3 10 [RuCI 2 (S)-XylylPhanePhos,(R,R)DPEN] 17 >99 75.7 11 [RuCi(S)-XylylPhanePhos,(R,R)DPEN] 17 97 71

BF

4 WO 2009/055912 PCT/CA2008/001905 76 TABLE 6. RESULTS OF THE HYDROGENATION OF 2-FLUORO ACETOPHENONE CATALYSED BY CATIONIC COMPLEXES OF RUTHENIUM. 5 0 OH

H

2 /Cat/KCOBu F 2-propanol, RT F entry Cat . Time(h) Conv.(%) ee (%) I [RuC(S-PPhos,S-DAIPEN)]BF 4 2 >99 80 2 [RuCI(S-PPhos,S-DAIPEN)]B(C 6 Fs) 4 2 >99 80.3 3 [RuCl(S-xyly]PPhos,S.-DAIPEN)]BF4 2 >99 95.3 4 [RuCI(S-xylylPPhos,S-DAIPEN)]B(C6F5)4 2 >99 92.4 5 [RuCl(S-BINAP,S-DAIPEN)]BF4 2 >99 80.7 6 [RuCI(S-BINAP,S-DAIPEN)]B(CrF5)4 2 >99 84.6 7 [RuCl2(S)-PhanePhos,(R,R)DPEN] 3 95 77.7 8 [RuCI(S)-PhanePhos,(RR)DPEN]BF4 3 93 80 9 [RuCI(S)PhanePhos,(R,R)DPEN]B(C6F5)4 3 98 67 10 [RuCl(S)-XylylPhne(R os,(R,R)DPEN 3 92 67.2 10 [RuC(S)-XylylPhanePhos,(RR)DPEN] 3 63 82 BF4 12 [RuCl(S)-XylylPhanePhos,(R,R)DPEN] 3 93 87.3 B(CrFS)4 WO 2009/055912 PCT/CA2008/001905 77 TABLE 7. RESULTS OF THE HYDROGENATION OF 1-(2,4.

DJMETHOXYPHENYL)ETHANONE CATALYZED BY RUTHENIUM 5 COMPLEXES OF PHANEPHOS, OMe O OMe oi

H

2 /Cat/IQOBu M o 2-Propanol, RT Entry Cat. Time(h) Conv.(%) ce (%) 1 [RuCl 2 (S)-PhanePhos,(R,R)DPEN] 3 >99 79.3 2 [RuCI(S)-PhanePhos,(R,R)DPEN]BF 4 3 >99 58,5 3 [RuCI(S)PhanePhos,(R,R)DPENB(C 6

F)

4 3 >99 75 4 [RuC12(S)-XylylPhanePhos,(R,R)DPEN] 3 >99 72 5 [RuC(S)-XylylPhanePhos,(R,R)DPEN] BF 4 3 >99 47 6 [RuCl(S)-XylylPhanePhos,(R,R)DPEN] 3 >99 57.7 B(C6F)4 101 WO 2009/055912 PCT/CA2008/001905 78 TABLE 8. RESULTS OF THE HYDROGENATION OF 1-(4 METHOXYPHENYL)PROPAN-2-ONE CATALYZED BY RUTHENIUM COMPLEXES OF PHANEPHOS.

H

2 /Cat/K'OBu 5 M0o 2-Propanol, RT MeO Entry Cat. Time(h) Conv.(%) ce (%) 1 [RuCl2(S)-PhanePhos,(R,R)DPEN] 5 99 81 2 [RuCI(S)-PhanePhos,(R,R)DPEN]BF 4 5 >99 -79 3 [RuCl(S)PhanePhos,(R,R)DPEN]B(C 6 FS)4 5 ->99 79 4 [RuC1 2 (S)-XylylPhanePhos,(R,R)DPEN) 5 >99 85 5 [RuCl(S)-XylylPhanePhos,(R,R)DPEN] BF 4 5 >88 75 6 [RuC(S)-XylylPhanePhos,(R,R)DPEN] 5 >99 78

B(C

6 FS)4 WO 2009/055912 PCT/CA2008/001905 79 TABLE 9. RESULTS OF THE HYDROGENATION OF ACETOPHENONE CATALYSED BY DICATIONIC COMPLEXES OF RUTHENIUM 0 OH Cat/K'OBu 5 2-propanol, RT Entry Complex Time(h) Conv.(%) ee (%) I [Ru(R-binap)(R,R-cydn)][BF 4

]

2 2 >99 85 2 [Ru(R-binap)(Ph 2 PCH2CH 2 NH2)] [BF4J 2 24 93 3 3 [Ru(1R,2R-(Ph 2

PC

6

H

4

CH

2

NH)

2

C

6 HIo)] [BE 4

]

2 24 94 10 S/Cat =830 10 WO 2009/055912 PCT/CA2008/001905 80 TABLE 10. RESULTS OF THE HYDROGENATION OF 2,3,3 TRIMETHYLINDOLENINE CATALYZED BY CATIONIC RUTHENIUM COMPLEXES. 5 Entry Cat Time (h) Conv. (%) e.e. (%) 1 [(R-binap)RuCI(RR-dach)]BF 4 17 57 30 2 [(R-binap)RuCI(PGly)]BF 4 17 5 40 3 [RuCI(PGIY) 2

}BF

4 17 62 4 [RuCI(R,R-cyP2N 2

)]BF

4 17 16 76 " S:C:B = 180;1:26, iPrOH, r.t., 150 psi WO 2009/055912 PCT/CA2008/001905 81 TABLE 11. CATALYTIC HYDROGENATION OF ACETOPHENONE USING CATIONIC IRON COMPLEXES 0 OH

H

2 /Cat/K'OBu 2-propanol, RT 5 Entry analyst C S:C:B T ("C) PH2 (atm) Time (h) (o4v. (e 1 6(a) 225:1:15 50 25 17 7 1 2 6(b) 225:1:15 50 25 17 3 8 3 6(c) 225:1:15 50 25 17 4 20 4 6(d) 200:1:8 50 25 17 4 20 5 6(e) 200:1:8 50 25 17 0 6 6(f) 200:1:8 50 25 17 3 7 6(h) 200:1:8 50 25 17 69 58 8 6(h) 200:1:8 50 25 17 96 63 9 6(h) 200:1:1 50 25 17 95 53 a S:C:B = 200:1:8, S= PhCOMe, C-catalyst, B = KO'Bu; [S]= 0.36 M in 5 mL of i Pr0H.

WO 2009/055912 TABLE 12: TRANSFER HYDROGENATION OF ACETOPHENONE USING CATIONIC IRON COMPLEXESA 0 OH Cat/K'OBu 2 roQPnoi, RT 5 Caqiyst T Corn. e.e Entry S :C:B Time (h) I 6(a) 200;1:10 25 19 ,0 2 6(a) 200:1:10 80 19 0 3 6(e) 200:1:10 80 19 0 4 6(f) 20:1:10 25 19 0 5 6(f) 200:1:10 80 18 19 22 6 6(g) 200:1:10 25 3 12 78 7 6(h) 200:1:10 25 3 6 60 8 6(h) 200:1:10 80 3 3- S= PhCOMe, C=catalyst, B= KO'Bu; []= 0.36 M in 5 mL of i-PrOH. Throughout this specification, unless the context requires otherwise, the word "comprise" or variations such as "comprises" or "comprising", will be understood to irnply the inclusion of a stated element or integer or method step or group of elements or integers or method steps but not the exclusion of any element or integer or method step or group of elements or integers or method steps. Reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that this prior art forms part of the common general knowledge in any country.

Claims (29)

1. A compound of the Formula (V) [Ru(P 2 )(N

2 )Xq(LB)n] r[Y~]r (V) wherein P 2 is a bidentate bisphosphino ligand of the Formula (VII): R 4 R 5 P-Q 1 -PR 6 R 7 (VII) wherein 4 5 6 R , R , R6 and R 7 are independently selected from C 6 -isaryl, Ci-20alkyl and C 3 . 20cycloalkyl, each being optionally substituted with one to five substituents independently selected from C 1 . 6 alkyl, fluoro-substituted C 1 . 6 alkyl, halo, Ci- 6 alkoxy, fluoro-substituted C 1 . 6 alkoxy and C 6 - 14 aryl; Q 1 is selected from unsubstituted or substituted C1-Cioalkylene and unsubstituted or substituted C1-Csalkenylene where the substituents on Q1 are independently selected from one or more of Ci- 6 alkyl, fluoro-substituted C 1 . 6 alkyl, halo, Ci- 6 alkoxy, fluoro-substituted C 1 . 6 alkoxy and unsubstituted or substituted C 6 - 14 aryl, and/or two substituents on Q1 are joined together to form, including the carbon atoms to which they are attached, one or more unsubstituted or substituted 5-20-membered monocyclic, polycyclic, heterocyclic, carbocyclic, saturated, unsaturated or metallocenyl ring systems, where the term substituted with respect to the Q 1 substituents means that one or more of the available hydrogen atoms on the group are replaced with Ci- 6 alkyl, fluoro-substituted C 1 . 6 alkyl, C1- 6 alkoxy, fluoro-substituted C1- 6 alkoxy, halo or C 6 -1 4 aryl; Q 1 is chiral or achiral; N 2 is a bidentate diamine ligand of the Formula (X): R R 9N-Q 6 -NR 2 0 R 21 (X) H: \aar\lnterwoven\NRPortbl\DCC\AAR\6711014_1.doc-5/09/2014 -85 R 18 and R 19 are independently selected from H, C 6 -isaryl, Ci-20alkyl and C 3 . iocycloalkyl, the latter three groups being optionally substituted with one to five substituents independently selected from C 1 . 6 alkyl, fluoro-substituted C 1 . 6 alkyl, halo, Ci- 6 alkoxy, fluoro substituted C 1 . 6 alkoxy and C 6 . 14 aryl, and at least one of R 8 and R 19 is H; Q 6 is selected from unsubstituted or substituted C1-Cioalkylene and unsubstituted or substituted C1-Csalkenylene where the substituents on Q6 are independently selected from one or more of Ci- 6 alkyl, fluoro-substituted C 1 . 6 alkyl, halo, Ci- 6 alkoxy, fluoro-substituted C 1 . 6 alkoxy and unsubstituted or substituted C 6 - 14 aryl, and/or two substituents on Q6 are joined together to form, including the carbon atoms to which they are attached, one or more unsubstituted or substituted 5-20-membered monocyclic, polycyclic, heterocyclic, carbocyclic, saturated, unsaturated or metallocenyl ring systems, where the term substituted with respect to the Q 6 substituents means that one or more of the available hydrogen atoms on the group are replaced with Ci- 6 alkyl, fluoro-substituted C 1 . 6 alkyl, C1- 6 alkoxy, fluoro-substituted C1- 6 alkoxy, halo or C 6 -1 4 aryl; Q 6 is chiral or achiral; R 2 0 and R 2 1 are independently selected from H, C 6 8 isaryl, Ci-20alkyl and C 3 . iocycloalkyl, the latter three groups being optionally substituted with one to five sub stituents independently selected from CI 6 alkyl, fluoro-substituted CI 6 alkyl, halo, Ci- 6 alkoxy, fluoro substituted C 1 . 6 alkoxy and C 6 . 14 aryl and at least one of R 2 0 and R 2 1 is H, or one of R 2 0 and R 2 1 are joined with a sub stituent on Q6 to form, together with the nitrogen atom to which R 2 0 and R 21 is attached, a pyridine ring and the other of R 2 0 and R 2 1 is non-existent; X is any anionic ligand; LB is any neutral Lewis base which is coordinated to Ru through a single atom; Y is any non-coordinating anion; n is 0, 1 or 2; q is 0 or 1; r is 1 or 2; and q + r = 2. H: \aar\lnterwoven\NRPortbl\DCC\AAR\6711014_1.doc-5/09/2014 - 86 2. The compound according to Claim 1, wherein R 4 , R 5 , R 6 and R 7 are independently selected from phenyl, Ci- 6 alkyl and C 3 .iocycloalkyl, each being optionally substituted with one to three substituents independently selected from C 1 . 4 alkyl, fluoro-substituted C 1 . 4 alkyl, halo, C 1 . 4 alkoxy and fluoro-substituted C 1 . 4 alkoxy; Q 1 is selected from unsubstituted or substituted CI-Csalkylene where the substituents on Q1 are independently selected from one to four CI 4 alkyl, fluoro-substituted CI 4 alkyl, halo, C 1 . 4 alkoxy, fluoro-substituted C 1 . 4 alkoxy, unsubstituted and substituted phenyl and substituted and unsubstituted naphthyl, or two substituents are joined together to form, including the carbon atoms to which they are attached, one or more unsubstituted or substituted phenylene, cyclohexylene, naphthylene, pyridylene or ferrocenylene groups; and Q 1 is chiral or achiral.

3. The compound according to Claim 2, wherein R 4 , R 5 , R 6 and R 7 are all cyclohexyl, phenyl, xylyl or tolyl.

4. The compound according to Claim 2, wherein the bis(phosphino) ligand of the Formula (VII) is selected from: 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl (BINAP); 2,2'-bis(diphenylphosphino)-5,5',6,6',7,7',8,8'-octahydro-1,1'-binaphthyl (HsBINAP); 2,2'-bis-(diphenylphosphino)-6,6'-dimethyl-1,1'-binaphthyl (6MeBINAP); 2,2'-bis-(di-p-tolylphosphino)-1-,1'-binaphthyl (Tol-BINAP); 2,2'-bis[bis(3-methylphenyl)phosphino]-1,1 '-binaphthyl; 2,2'-bis[bis(3,5-di-tert-butylphenyl)phosphino]-1,1 '-binaphthyl; 2,2'-bis[bis(4-tert-butylphenyl)phosphino]-1,1 '-binaphthyl; 2,2'-bis[bis(3,5-dimethylphenyl)phosphino]-1,1'-binaphthyl (Xyl-BINAP); 2,2'-bis[bis(3,5-dimethyl-4-methoxyphenyl)phosphino]-1,1'-binaphthyl (Dmanyl BINAP); 2,2'-bis[bis-(3,5-dimethylphenyl)phosphino]-6,6'-dimethyl-1,1'-binaphthyl (Xyl 6MeBINAP); 3,3'-bis-(diphenylphosphanyl)-13,13'-dimethyl-12,13,14,15,16,17,12',13',14', 15',16',17'-dodecahydro-11H,11'H-[4,4']bi[cyclopenta[a]phenanthrenyl]; H: \aar\lnterwoven\NRPortbl\DCC\AAR\6711014_1.doc-5/09/2014 - 87 PCy 2 4Z PCy 2 Fe wherein Cy is C 5 -gcycloalkyl; OCH 3 N H 3 CO PAr 2 H3CO PAr2 N, OCH 3 where Ar is phenyl (PPhos), xylyl (XylPPhos) or tolyl (TolPPhos); PAr2 (PAr2 where Ar is phenyl (PhanePhos), xylyl (XylPhanePhos) or tolyl (TolPhanePhos); and optical isomers thereof and mixtures of optical isomers in any ratio.

5. The compound according to any one of Claims 1 to 4, wherein Q 6 is selected from unsubstituted or substituted CI-Csalkenylene where the substituents on Q6 are independently selected from one to four of CI 6 alkyl, fluoro-substituted CI 6 alkyl, halo, Ci- 6 alkoxy, fluoro substituted C 1 .

6 alkoxy and unsubstituted or substituted phenyl; and/or two substituents on Q6 are joined together to form, including the carbon atoms to which they are attached, one or more unsubstituted or substituted phenyl, naphthyl or ferrocenyl ring systems; and Q 6 is chiral or achiral. H: \aar\lnterwoven\NRPortbl\DCC\AAR\6711014_1.doc-5/09/2014 - 88 6. The compound according to any one of Claims Ito 5, whereinR ", R a, R' are all H.

7. The compound according to any one of Claims I to 5, wherein R20 or R are joined with a substituent on Q6 to form, together with the nitrogen atom to which R20 or R2 is attached, a pyridine ring and the other of one of R20 or R2 is not present.

8. The compound according to any one of Claims I to 5, wherein N 2 is selected from: 1,2-diaminopropane; 1,3-diaminopropane; 1,4-diaminopropane; 2,3-diaminobutane; 1,2-cyclopentanediamine; 1,2-cyclohexanediamine; 1,1 -diphenyl ethyl enediamine (DPEN); 1,1 -di(p-methoxyphenyl)ethylenediamine; 1,1-di(3,5-dimethoxyphenyl)ethylenediamine; 1,1 -dinaphthylethylenediamine; 1,2-cycloheptanediamine; 2,3-dimethylbutanediamine; 1-methyl-2,2-diphenylethylenediamine (DACH or CYDN); 1 -isobutyl -2,2-diphenylethylenediamine; 1 -isopropyl-2,2-diphenylethylenediamine; 1 -benzyl -2,2-diphenylethylen-ediamine; 1-methyl-2,2-di(p-methoxyphenyl)ethylenediamine (DAMEN); 1-isobutyl-2,2-di(p-methoxyphenyl)-ethylenediamine (DAIBEN); 1-isopropyl-2,2-di(p-methoxyphenyl)ethylenediamine (DAIPEN); 1-benzyl-2,2-di(p-methoxyphenyl)ethylenediamine; 1-methyl-2,2-di(3,5-dimethoxyphenyl)ethylenediamine; 1-isopropyl-2,2-di(3,5-dimethoxyphenyl)ethylenediamine, H: \aar\lnterwoven\NRPortbl\DCC\AAR\6711014_1.doc-5/09/2014 - 89 1 -isobutyl-2,2-di(3,5 -dimethoxy-phenyl)ethylenediamine; 1 -benzyl-2,2-di(3,5 -dimethoxyphenyl)ethylenediamine; 1 -methyl-2,2-dinaphthyl ethylenediamine; 1 -isobutyl -2,2-dinaphthylethylene-diamine; 1 -isopropyl-2,2-dinaphthyl ethylenediamine; 1 -benzyl -2,2-dinaphthylethylenedi amine; Rf -Re N NH 2 wherein Re is H, CI 6 alkyl, fluoro-substituted CI 6 alkyl or aryl and Ri is H, halo, C 1 . 6 alkyl, fluoro-sub stituted-C 1- 6 alkyl, C 2 - 6 alkenyl, C 2 - 6 alkynyl, C3- 7 cycloalkyl, C1- 6 alkoxy, fluoro-sub stituted-C 1 6 alkoxy or C 6 .1 4 aryl; and optical isomers thereof and mixtures of optical isomers in any ratio.

9. The compound according to any one of Claims 1-8, wherein X is selected from halo, Ci- 6 alkoxy, carboxylate, sulfonates and nitrates.

10. The compound according to any one of Claims 1-9, wherein LB is selected from acetonitrile, DMF and pyridine.

11. The compound according to any one of Claims 1-10, wherein Y is selected from: a) OTf; b) BF 4 ; c) PF 6 ; d) B(C 1 . 6 alkyl) 4 ; e) B(fluoro-substituted-C 1 6 alkyl) 4 ; f) B(C 6 -isaryl) 4 , wherein aryl is unsubstituted or substituted 1-5 times with fluoro, CI. 4 alkyl or fluoro-substituted CI. 4 alkyl; H: \aar\lnterwoven\NRPortbl\DCC\AAR\6711014_1.doc-5/09/2014 -90 (R) -~e B -,0( ) g) ( , 0(R , R9 is independently halo, CI 4 alkyl or fluoro-substituted-C1. 4 alkyl and x and x' are independently an integer between 1 and 4; (Rh)Y -- -Rh (Rhy (h~y h) , wherein Rhis independently halo, C 1 . 4 alkyl or fluoro-substituted-C 1 . 4 alkyl and y and y' are independently an integer between 1 and 6; i) Al(CI 6 alkyl) 4 ; j) Al(fluoro-substituted-C 1 . 6 alkyl) 4 ; k) Al(C 6 8 isaryl) 4 , wherein aryl is unsubstituted or substituted 1-5 times with fluoro, CI 4 alkyl or fluoro-substituted CI 4 alkyl; 1) Al(-O-Ci- 6 alkyl) 4 ; m) Al(-O-fluoro-sub stituted-C 1 6 alkyl) 4 ; n) Al(-O-C 6 -isaryl) 4 , wherein aryl is unsubstituted or substituted 1-5 times with fluoro, CI 4 alkyl or fluoro-substituted CI 4 alkyl; o) a carborane; p) a bromocarborane; and q) a phosphate.

12. The compound according to Claim 11, wherein the phosphate anion is of the formula 0o ,0 P RJ 0 0 RJ 0N / \ / \ / wherein Ri and R are independently selected from halo, CI 4 alkyl, fluoro-substituted C 1 . 4 alkyl or C 6 -isaryl. H: \aar\lnterwoven\NRPortbl\DCC\AAR\6711014_1.doc-5/09/2014 - 91

13. The compound according to Claim 11, wherein the carborane is CBIIHu.

14. The compound according to Claim 11, wherein the bromoca rborane is CBu 1 H 6 Br 6 .

15. The compound according to any one of Claims 11-14, wherein Y is chiral.

16. A process for preparing a compound of any one of Claims 1-15, comprising combining a compound of the formula: Ru(P 2 )(N 2 )X 2 (XI) wherein P 2 , N 2 , and X are as defined in any one of Claims 1-9, with one or two molar equivalents of an anion abstracting agent and optionally a non- or weakly-coordinating Lewis Base, and reacting under conditions to form the compound and optionally isolating the compound.

17. A process for preparing a compound of any one of Claims 1-8, comprising combining a precursor ruthenium compound with one or two molar equivalents of an anion abstracting agent, and optionally a Lewis Base and reacting under conditions to form a cationic or dicationic precursor ruthenium compound and combining the cationic or dicationic precursor ruthenium compound with one or more P 2 or N 2 , or ligands, as defined in any one of Claims 1 8, and optionally a non- or weakly-coordinating Lewis Base, under conditions to form the compound and optionally isolating the compound.

18. The process according to Claim 17, wherein the precursor ruthenium compound is of the formula [RuX 2 (p-ligand)] 2 or RuX 2 (ligand), wherein X is as defined in Claim 1 and ligand is any displaceable ligand. H: \aar\lnterwoven\NRPortbl\DCC\AAR\6711014_1.doc-5/09/2014 - 92

19. The process according to Claim 18, wherein the displaceable ligand is p-cymene, benzene, cyclooctadiene (COD) or norbornadiene (NBD).

20. The process according to Claim 19, wherein the displaceable ligand is p-cymene or NBD.

21. The process according to Claim 18, wherein the precursor metal compound is of the formula RuX 2 (P 2 )(LB)n, wherein X, P 2 and LB are as defined in Claim 1 and n is 1 or 2.

22. The process according to Claim 21, wherein (P 2 ) is BINAP and LB is DMF or pyridine.

23. The process according to any one of Claims 16-22, wherein the anion abstracting agent is a salt of a non-coordinating counter anion Y, wherein Y is as defined in any one of Claims 11-15.

24. A method for catalyzing a synthetic organic reaction comprising combining starting materials for the reaction with a compound according to any one of Claims 1-15 under conditions for performing the reaction.

25. The method according to Claim 24, wherein the synthetic organic reaction is selected from hydrogenation, transfer hydrogenation, hydroformylation, hydrosilylation, hydroboration, hydroamination, hydrovinylation, hydroarylation, hydration, oxidation, epoxidation, reduction, C-C and C-X bond formation, functional group interconversion, kinetic resolution, dynamic kinetic resolution, cycloaddition, Diels-Alder, retro-Diels-Alder, sigmatropic rearrangement, electrocyclic reactions, ring-opening and/or ring-closing olefin metathesis, carbonylation and aziridination.

26. The method according to Claim 25, wherein the C-C and C-X bond formation reaction is selected from Heck, Suzuki-Miyaura, Negishi, Buchwald-Hartwig Amination, a-Ketone Arylation, N-Aryl Amination, Murahashi, Kumada and Stille reactions. H: \aar\lnterwoven\NRPortbl\DCC\AAR\6711014_1.doc-5/09/2014 - 93

27. The method according to Claim 25, wherein the reaction is hydrogenation or transfer hydrogenation

28. The method according to any one of Claims 24-27 wherein the reaction is regioselective, chemoselective, stereoselective or diastereoselective.

29. A compound according to any one of Claims I to 15 or a process according to any one of Claims 16 to 23 or a method according to any one of Claims 24 to 28 substantially as herein described with reference to the Figures and/or Examples.